Разработка оригинального анксиолитика с антиалкогольной активностью на основе фармакологического изучения новых производных холецистокинина

Список литературы

1. Анохина, И.П. и др. Пат. РФ №БШ2 142 813/С1 от 1999. «Тетрапептид Тгр-їчПе-Азр-РІ7еМН-СН (СНЗ)2, обладающий анксиолитической активностью.»
2. Ашмарин, И.П. Глипролины в составе регуляторных трипептидов. Текст. / И. П. Ашмарин // нейрохимия 2007. — Т.24. — № 1. — С.5−7.
3. Бойко, С.С. Экспериментальное исследование фармакокинетики триптофансодержащего дипептида ГБ-115 Текст. / С. С. Бойко, Г. Б. Колыванов, В. П. Жердев, Т. А. Гудашева, Е. В. Кирьянова, С. Б. Середенин // Бюлл. Эксп. Биол. и Мед. -2007. Т. 144. — № 9. — С.285−287.
4. Васюк, Ю.А. Депрессивные и тревожные расстройства в кардиологии. Текст. / Ю. А. Васюк, Т. В. Довженко, Е. Л. Школьник, Е. И. Ющук. Москва: Анахарсис., 2011. — С.200.
5. Вельтищев, Д-Ю. Генерализованное тревожное расстройство: эпидемиология, патогенез, диагностика и фармакотерапия Текст. / Д. Ю. Вельтищев, А. С. Марченко // Псих, расстройства в общей медицине 2011. — № 1.
6. Виглинская, И. В. Разработка новых методов фармакотерапии алкоголизма на основе анализа генетических исредовых факторов формирования алкогольных расстройств: Дисс. на соиск. уч.ст. док.биол.наук / И. В. Виглинская Москва, 1997. -С.198 с.
7. Виглинская, И.В. Исследование анксиолитического действия нового производного 2-меркаптобензимидазола у МЯ и ММ1А крыс Текст. / И. В. Виглинская, СБ. Середенин, Л. Г. Колик // Эксп. Клин. Фармакол. 1997. — Т.60. — № 3. — С.3−5.
8. Воронина, Т.А. Перспективы поиска новых анксиолитиков Текст. / Т. А. Воронина, С. Б. Середенин // Эксп. клин, фармакол. -2002.-№ 5.-С.4−17.
9. Гарибова, Т.Л. Влияние блокатора кальциевых каналов нифедипина на тревогу и судорожные проявления синдрома отмены у крыс после отмены длительного введения диазепама. Текст. / Т. Л. Гарибова, Е. А. Вальдман, Т. А. Воронина,
10. B.А.Крайнева // Бюлл. Эксп. Биол. и Мед. 1998. — Т. 125. — № 5.1. C.53−54.
11. Гудашева, Т.А. Дизайн и синтез дипептидных аналогов холецистокинина-4 с анксиолитическими и анксиогенными свойствами. Текст. / Т. А. Гудашева, Е. П. Кирьянова, Л. Г. Колик, М. А. Константинопольский, С. Б. Середенин // Биоорг.Хим. 2007. — Т.ЗЗ. — № 4. — С.413−20.
12. Гудашева, Т.А. Синтез, конформационный анализ ианксиолитическая активность ретропептидных аналогов холецистокинина-4 Текст. / Т. А. Гудашева, В. П. Лезина, Е. П. Кирьянова, В. С. Троицкая, Л. Г. Колик, С. Б. Середенин // Хим-фарм.Ж. 2006. — Т.40. — № 7. — С.367−72.
13. Коваленко, Л.П. Противовоспалительные свойства ноопепта. Текст. / Л. П. Коваленко, М. Г. Мирамедова, С. В. Алексеева, Т. А. Гудашева, Р. У. Островская, С. Б. Середенин // Эксп. Клин. Фармакол 2002. — Т.65. — № 2. — С.53−55.
14. Колик, Л.Г. Сравнительное исследование анксиолитических и антиалкогольных свойств новых антагонистов ССК-2 рецепторов у инбредных животных с различной эмоциональностью: Диссер. на соиск.уч.ст.канд.биол.наук. / Л. Г. Колик Москва, 2002.
15. Колик, Л.Г. Экспериментальное изучение антидепрессивных свойств ГБ-115 Текст. / Л. Г. Колик // Эксп. Клин. Фармакол. 2011. — Т.74. — № 1. — С.3−5.
16. Колик, Л.Г. Генетическая зависимость психотропных эффектов оригинального пептидного антагониста центральных холецистокининовых рецепторов. Текст. / Л. Г. Колик, Т. А. Гудашева, С. Б. Середенин // Медицинская генетика. 2005. -Т.4. — № 5. — С.206−207.
17. Колик, Л.Г. Фармакогенетическое исследование свойств новых антагонистов холецистокининовых рецепторов у животных с различным уровнем эмоциональности. Текст. / Л. Г. Колик, Т. А. Гудашева, С. Б. Середенин // Бюлл. Эксп. Биол. и Мед. 2003. — № 6. — С.519−23.
18. Колик, Л.Г. Об участии холецистокининовой системы в реализации анксиолитических эффектов дипептида ГБ-115 Текст. / Л. Г. Колик, Т. А. Гудашева, С. Б. Середенин // Бюлл. экспер. биол. и мед. 2012. — Т. 153. — № 6. — С.28−32.
19. Колик, Л.Г. Характер проявления антиноцицептивных и анксиолитических свойств соединения ГБ-115 в аспекте взаимодействия холецистокининовой и опиоидергической систем. Текст. / Л. Г. Колик, В. Н. Жуков, С. Б. Середенин // Эксп.
20. Клин. Фармакол. 2007а. — Т.70. — № 2. — С.8−11.
21. Колик, Л.Г. Влияние соединения ГБ-115 на индуцированную морфином анальгезию. Текст. / Л. Г. Колик, В. Н. Жуков, С. Б. Середенин // Бюлл. Эксп. Биол. и Мед. 20 076. -Т. 143. — № 6. — С.645−647.
22. Колик, Л.Г. Влияния дипептида ГБ-115 на тревожную реакцию у крыс при моделировании «синдрома отмены» бензодиазепинов Текст. / Л. Г. Колик, И. А. Кадников, В. Н. Жуков, Т. А. Гудашева, С. Б. Середенин // Эксп. Клин. Фармакол. 2011. -Т.74.-№ 10.-С.52−56.
23. Кошкина, Е.А. Заболеваемость психическими и поведенческими расстройствами, связанными с употреблением психоактивных веществ, в Российской Федерации в динамике за 5 лет Текст. / Е. А. Кошкина // Вопросы наркологии 2011. — № 1. -С. 17−27.
24. Кошкина, Е.А. Наркологическая помощь больным алкоголизмом в 2010 г. Текст. / Е. А. Кошкина, В. В. Киржанова,
25. B.М.Гуртовенко // Вопросы наркологии 2011. — № 6. — С. 12−25.
26. Крепелин, Э. Введение в психиатрическую клинику, 1900 Текст. / Э.Крепелин. БИНОМ, 2004. — С.493.
27. Лукутина, А.И. Психические нарушения у пациентов с травмой опорно-двигательного аппарата: Автореф. дис. на соиск. учен. степ. канд. мед. наук. / А. И. Лукутина Москва, 2008.1. C.22.
28. Молодавкин, Г. М. Зависимость силы анксиолитического эффекта транквилизаторов от уровня тревоги в конфликтной ситуации. Текст. / Г. М. Молодавкин, Т. А. Воронина // Бюлл. Эксп. Биол. Мед. 1996. — № 1. — С.63−66.
29. Овчинников, Ю.А. Биоорганическая химия Текст. / Ю. А. Овчинников. Москва: «Просвещение», 1987. — С. 173−175.
30. Рудько, О.И. Долговременное действие пептидных регуляторов индукторов тревожности: отложенные и инверсные эффекты.: Автореферат диссертации на соискание ученой степени кандидата биологических наук / О. И. Рудько — Москва, 2008.
31. Середенин, С.Б. Фармакологическая регуляция . эмоционально-стрессовых состояний. Текст. / С. Б. Середенин // Вестник РАМН. 2003. — № 12. — С.36.
32. Середенин, С.Б. Влияние мембраномодулятора 3-оксипиридина на эмоционально-стрессовую реакцию и связывание НЗ-диазепама в мозге инбредных мышей. Текст. / С. Б. Середенин, Ю. А. Бледнов, М. Л. Гордей // Хим.-Фарм. журнал. 1987. — № 2.-С. 134.
33. М.А.Яркова, В. Л. Савельев, Т. Л. Гарибова, Е. А. Вальдман // Вестник РАМН 1998. — Т.4. — № 11. — С.3−9.
34. Середенин, С.Б. и др. Пат. РФ № 2 227 144 от 2004. «Замещенные триптофан-содержащие дипептиды с холецистокининонегативной или холецистокининопозитивной активностью».
35. Середенин, С.Б. и др. Пат. РФ №№ 2 429 874 от 16.04.2010. «Анальгетическое средство для купирования висцеральной боли.».
36. Смулевич, А.Б. Транквилизаторы — производные бензодиазепинов в психиатрии, психосоматике и общей медицине. Текст. / А. Б. Смулевич, М. Ю. Дробижев, С. В. Иванов. -Москва, 2005.
37. Судаков, С.К. Церебральные механизмы опиатной зависимости. Текст. / С. К. Судаков, К. В. Судаков // Наркология. -2003. Т.1. — С.38.
38. Шабанов, П.Д. Наркомании: патопсихология, клиника, реабилитация Текст. / П. Д. Шабанов, О.Ю.Штакельберг- Под ред. А. Я. Гриненко. СПб.: Лань, 2000. — С.368.
39. Шептулин, A.A. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни Текст. / А. А. Шептулин // Рос. журн.гастроэнтерол. гепатол. колопроктол. 2010. — Т.20. — № 6. — С.81−85.
40. Шипаева, Е.В. Иммуннокорригирующие свойства дипептида ГБ-115 Текст. / Е. В. Шипаева, Л. П. Коваленко, С. Хайдуков, Л. Г. Колик, Т. А. Гудашева, А. Д. Дурнев, С. Б. Середенин // Бюлл. Эксп. Биол. и Мед. 2008. — Т. 145. — № 5. -С.548−551.
41. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (4th ed.) (DSM-IV). Text. / American Psychiatric Association // In: / Washington, DC, 1994.
42. Abelson, J.L. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Text. / J.L.Abelson, SKhan, I. Liberzon, E.A.Young // Depress Anxiety. 2007. — V.24. — N1. -P.66−76.
43. Abelson, J.L. Dose response of adrenocorticotropin and Cortisol to the CCK-B agonist pentagastrin. Text. / J.L.Abelson, I. Liberzon // Neuropsychopharmacology. 1999. — V.21. — N4. — P.485−94.
44. Adamcio, B. Chronic psychosocial stress in the absence of social support induces pathological pre-pulse inhibition in mice. Text. / B. Adamcio, U. Havemann-Reinecke, H. Ehrenreich // Behav. Brain Res. 2009. — V.204. — N1. — P.246−249.
45. Adams, J.B. A double-blind, placebo-controlled study of a
46. Adell, A. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety. Text. / A. Adell // IDrugs. 2010. — V.13. — N12. — P.900−10.
47. Agmo, A. Conditioned place preference produced by infusion of Met-enkephalin into the medial preoptic area. Text. / A. Agmo, M. Gomez // Brain Res 1991. — N550. — P.343−346.
48. Akagi, K. Calcium oscillations in single cultured Chinese Hamster Ovary cells stably transfected with cloned human cholecystokinin (CCK)B receptor. Text. / K. Akagi, T. Nagao, T. Urushidani // Jpn J Pharmacol. 1997. — V.75. — N1. — P.33−42.
49. Alderman, C.P. Pharmacotherapy for post-traumatic stress disorder. Text. / C.P.Alderman, L.C.McCarthy, A.C.Marwood // Expert Review of Clinical Pharmacology 2009. — V.2. — N1. — P.77
50. Alexander, W. Pharmacotherapy for Post-traumatic Stress Disorder In Combat Veterans: Focus on Antidepressants and Atypical Antipsychotic Agents. Text. / W. Alexander // P&T. 2012. — V.37. -N1. — P.32−8.
51. Allaman, I. Astrocyte-neuron metabolic relationships: for better and for worse. Text. / I. Allaman, M. Belanger, P.J.Magistretti // Trends Neurosci. 2011. — V.34. — N2. — P.76−87.
52. Allison, C. Diazepam withdrawal-induced anxiety and place aversion in the rat: differential effects of two chronic diazepam treatment regimes. Text. / C. Allison, L.A.Claase, J.A.Pratt // Behav Pharmacol. 2002. — V.13. — N5−6. — P.417−25.
53. Allison, C. Differential effects of two chronic diazepam treatment regimes on withdrawal anxiety and AMPA receptor characteristics Text. / C. Allison, J.A.Pratt // Neuropsychopharmacology. 2006. — V.31. — N3. — P.602−19.
54. Alonso, J. Overview of Key Data From the European Study of the Epidemiology of Mental Disorders (ESEMeD). Text. / J. Alonso, J.P.Lepine // J Clin Psychiatry 2007. — V.68. — P.3−9.
55. Altar, C.A. Cholecystokinin receptor subtypes and neuromodulation. Text. / C.A.Altar // Prog Neuropsychopharmacol Biol Psychiatry 1989. — V.13. — P.381−93.
56. Alttoa, A. Effect of CCK1 and CCK2 receptor blockade on amphetamine-stimulated exploratory behavior and sensitization to amphetamine. Text. / A. Alttoa, J. Harro // Eur Neuropsychopharmacol. 2004. — V.14. — N4. — P.324−31.
57. Andre, J. Involvement of cholecystokininergic systems inanxiety-induced hyperalgesia in male rats: behavioral and biochemical studies. Text. / J. Andre, B. Zeau, M. Pohl, F. Cesselin, J.J.Benoliel, C. Becker // J Neurosci. 2005. — V.25. — N35. — P.7896−904.
58. Anokhina, I.P. Involvement of the neuropeptide cholecystokinin in the mechanisms of regulation of emotions and craving. Text. / I.P.Anokhina, T.V.Proskuriakova // Vestn Ross Akad Med Nauk 2002. — V.6. — P.36−40.
59. Aouizerate, B. Neurobiology and pharmacotherapy of social phobia Text. / B. Aouizerate, C. Martin-Guehl, J. Tignol // Encephale. -2004. V.30. -N4. -P.301−13.
60. Ardayfio, P. Anxiogenic-like effect of chronic corticosterone in the light-dark emergence task in mice. Text. / P. Ardayfio, K.S.Kim // Behav. Neurosci. 2006. — V. l20. — N2. — P.249−256.
61. Argyropoulos, S.V. Brain function in social anxiety disorder. Text. / S.V.Argyropoulos, C.J.Bell, D.J.Nutt // Psychiatr Clin North Am. 2001. — V.24. — N4. — P.707−22.
62. Ashton, H. Guidelines for the rational use of benzodiazepines: when and what to use. Text. / H. Ashton // Drugs 1994. — N48. -P.25⁰.
63. Baber, N.S. The role of CCK caerulein, and CCK antagonists in nociception. Text. / N.S.Baber, C.T.Dourish, D.R.Hill // Pain. 1989. — V.39. -N3. -P.307−28.
64. Bahi, A. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice. Text. / A. Bahi, Y.S.Mineur, M.R.Picciotto // Biol. Psychiatry. -2009. V.66. — N12. — P. l 139−1146.
65. Bailey, K.R. Anxiety-Related Behaviors in Mice. Text. / K.R.Bailey, J.N.Crawley // In: Methods of Behavior Analysis in Neuroscience. / Eds.: Buccafusco JJ CRC Press, 2009.
66. Baker, D.G. Posttraumatic Stress Disorder: Emerging Concepts of Pharmacotherapy Text. / D.G.Baker, C.M.Nievergelt, V.B.Risbrough // Expert Opin Emerg Drugs. 2009. — V.14. — N2. -P.251−272.
67. Baldwin, D.B. Paroxetine in social phobia/social anxiety disorder: randomised, double-blind placebo-controlled study. Text. / D.B.Baldwin, J. Bobes, D.J.Stein, I. Scharwachter, M. Faure // Br J Psychiatry 1999. — N175. — P.120−6.
68. Ballenger, J.C. Current treatments of the anxiety disorders in adults. Text. / J.C.Ballenger // Biol Psychiatry. 1999. — V.46. -Nil. -P. 1579−94.
69. Ballenger, J.C. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. Text. / J.C.Ballenger, J.R.Davidson, Y. Lecrubier // J Clin Psychiatry. 2001. — V.62. — Nsuppl. l 1. — P.53−58.
70. Ballenger, J.C. Kindling as a model for alcohol withdrawalsyndromes. Text. / J.C.Ballenger, R.M.Post // Br J Psychiatry 1978.- N133. P.1−14.
71. Balon, R. Calcium channel blockers for anxiety disorders? Text. / R. Balon, C. Ramesh // Ann Clin Psychiatry. 1996. — V.8. -N4. -P.215−20.
72. Bannon, A.W. Behavioral characterization of neuropeptide Y knockout mice. Text. / A.W.Bannon, J. Seda, M. Carmouche, J.M.Francis, M.H.Norman, B. Karbon, M.L.McCaleb // Brain Res. -2000. V.868. -Nl. -P.79−87.
73. Barlow, D.H. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. Text. / D.H.Barlow, J.M.Gorman, M.K.Shear, S.W.Woods // JAMA.- 2000. V.283. — N18. — P.2529−36.
74. Bartz, J.A. Is obsessive-compulsive disorder an anxiety disorder? Text. / J.A.Bartz, E. Hollander // Prog Neuropsychopharmacol Biol Psychiatry. 2006. — N30. — P.338−352.
75. Bateson, A.N. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Text. / A.N.Bateson // Curr Pharm Des 2002. — V.8. — N1. — P.5−21.
76. Becker, C. Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat. Text. / C. Becker, M. Hamon,
77. JJ.Benoliel // Neuropharmacology. 1999. — V.38. — N4. — P.525−3.
78. Becker, C. Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat. Text. / C. Becker, M.N.Thiebot, Y. Touitou, M. Hamon // J Neurosci. 2001. — V.21. — N1. — P.262−9.
79. Beinfeld, M.C. An introduction to neuronal cholecystokinin. Text. / M.C.Beinfeld // Peptides 2001a. — N22. — P. 1197−200.
80. Beinfeld, M.C. Distribution of cholecystokinin (CCK) in the rat lower brain stem nuclei. Text. / M.C.Beinfeld, M. Palkovits // Brain Res 1982. -N238. -P.260−5.
81. Belcheva, I. Asymmetry in behavioral responses to cholecystokinin microinjected into rat nucleus accumbens and amygdala. Text. / I. Belcheva, S. Belcheva, V. Petkov, V.D.Petkov //
82. Neuropharmacology 1994. — V.33. — P.995−1002.
83. Belzung, C. Measuring normal and pathological anxiety-like behaviour in mice: a review. Text. / C. Belzung, G. Griebel // Behav. Brain Res. 2001. — V.125. — N1−2. — P.141−149.
84. Belzung, C. Anxiety from a phylogenetic perspective: is there a qualitative difference between human and animal anxiety? Text. / C. Belzung, P. Philippot // Neural Plast. 2007. — P.59 676.
85. Berrendero, F. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Text. / F. Berrendero, A. Castane, C. Ledent, M. Parmentier, R. Maldonado, O. Valverde // Eur J Neurosci 2003. — N17. — P.315−324.
86. Berridge, K.C. The mind of an addicted brain: neural sensitization of wanting versus liking. Text. / K.C.Berridge, T.E.Robinson // Curr Direct Psychol. Sci 1995. — V.4. — P.71−6.
87. Berridge, M.J. Inositol phosphates and cell signaling. Text. / M.J.Berridge, R.F.Irvine // Nature 1989. — V.341. — P. 197−205.
88. Bertoglio, L.J. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats. Text. / L.J.Bertoglio, H.Jr.Zangrossi // Brain Res. -2005. V.1059. -Nl. -P.46−51.
89. Beuzen, A. Link between emotional memory and anxiety states: a study by principal component analysis. Text. / A. Beuzen, C. Belzung // Physiol. Behav. 1995. — V.58. — N1. — P. 111−118.
90. Blizard, D.A. The Maudsley reactive and nonreactive strains: a North American perspective. Text. / D.A.Blizard // Behav Genet. -1981. -V.ll. N5. -P.469−89.
91. Bock, M.G. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. Text. / M.G.Bock, R.M.DiPardo, B.E.Evans, K.E.Rittle, W.L.Whitter // J. Med. Chem. 1989. — V.32.1. N1. P. 13−16.
92. Bohme, G.A. The ureidoacetamides, a novel family of non-peptide CCK-B/gastrin antagonists. Text. / G.A.Bohme, P. Bertrand, C. Guyon, M. Capet, C. Pendley, J.M.Stutzmann, G. Martin, J.C.Blanchard // Ann. NY Acad. Sci. 1994. — V.713. — P. l 18−120.
93. Bork, M.G. Development of non-peptide cholecystokinin type B receptor antagonists. Text. / M.G.Bork // Drugs of the Future. -1991. V. 16. — N7. — P.631−640.
94. Borsini, F Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Text. / FBorsini, J. Podhorna, D. Marazziti //Psychopharmacology (Berl.) 2002. — N163. — P. 121−141.
95. Bosshart, H. Withdrawal-induced delirium associated with a benzodiazepine switch: a case report. Text. / H. Bosshart // J Med Case Reports. 2011. — V.5. — N1. — P.207.
96. Bourin, M. Two faces of cholecystokinin: anxiety and schizophrenia. Text. / M. Bourin, M. Malinge, E. Vasar, J. Bradwejn // Fundam. Clin. Pharmacol. 1996. — V.10. — P. l 16−126.
97. Bourin, M. Animal models of anxiety in mice. Text. / M. Bourin, B. Petit-Demouliere, B.N.Dhonnchadha, M. Hascoet // Fundam Clin. Pharmacol. 2007. — V.21. — N6. — P.567−574.
98. Bouwknecht, J.A. Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Text. /
99. J.A.Bouwknecht, R. Paylor // Behav. Pharmacol. 2008. — V.19. — N5−6. — P.385−402.
100. Bradwejn, J. Neurobiological investigations into the role of cholecystokinin in panic disorder. Text. / J. Bradwejn // J Psychiatry Neurosci. 1993. — V.18. — N4. — P. 178−188.
101. Bradwejn, J. Cholecystokinin and panic disorder. Text. / J. Bradwejn // In: Cholecystokinin and Anxiety: From Neuron to Behavior / Eds.: J. Bradwejn, E. Vasar Austin: RG Landes Company, 1995. — P.73−86.
102. Bradwejn, J. Imipramine antagonizes the panicogenic effects of CCK-4 in panic disorder patients. Text. / J. Bradwejn, D. Koszycki // Am. J. Psychiatry 1994. — V. 151. — P.261 -263.
103. Bradwejn, J. The cholecystokinin hypothesis of anxiety and panic disorder. Text. / J. Bradwejn, D. Koszycki // Ann N Y Acad Sei. 1994. — V.713. -P.273−82.
104. Bradwejn, J. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Text. / J. Bradwejn, D. Koszycki, L. Annable, A.C.du Tertre, S. Reines, C. Karakanias // Biol. Psychiatry 1992. — V.32. — P.903−912.
105. Bradwejn, J. The effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers. Text. / J. Bradwejn, D. Koszycki, A.C.du Tertre, M. Paradis, M. Bourin // Psychopharmacology (Berlin) 1994b. — P.257−261.
106. Bradwejn, J. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Text. / J. Bradwejn, D. Koszycki,
107. C.Shriqui // Arch. Gen. Psychiatry 1991. — V.48. — P.603−610.
108. Brady, K.T. The role of stress in alcohol use, alcoholism treatment, and relapse. Text. / K.T.Brady, S.C.Sonne // Alcohol Res Health 1999. — N23. — P.263−271.
109. Braida, D. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Text. / D. Braida, V. Limonta, V. Capurro, P. Fadda, T. Rubino, D. Parolaro, M. Sala // Biol Psychiatry. 2008. — V.63. — N3. — P.286−92.
110. Brambilla, F. Lymphocyte cholecystokinin concentration in panic disorder. Text. / F. Brambilla, L. Bellodi, G. Perna, A. Garberi, P. Sacerdote // Am. J. Psychiatry 1993. — V. 150. — P. 1111 -1113.
111. Breese, G.R. Stress enhancement of craving during sobriety: a risk for relapse. Text. / G.R.Breese, K. Chu, C.V.Dayas, D. Funk,
112. D.J.Knapp, G.F.Koob, D.A.Le, L.E.O'Dell, D.H.Overstreet, R. Sinha, G.R.Valdez, F. Weiss, T. Roberts // Alcohol Clin Exp Res. 2005a. -V.29. — N2. — P. 185−95.
113. Breese, G.R. Stress-induced anxiety-like behavior during abstinence from previous chronic ethanol exposure. Text. / G.R.Breese, D.J.Knapp, D.H.Overstreet // Alcohol Clin Exp Res -2004a. -V.28. -P.191A.
114. Breese, G.R. Conceptual framework for the etiology of alcoholism: a «kindling'Vstress hypothesis. Text. / G.R.Breese,
115. D.H.Overstreet, D.J.Knapp // Psychopharmacology (Berl). 2005c. -V.178. — N4. — P.367−80.
116. Breese, G.R. Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Text. / G.R.Breese, R. Sinha, M. Heilig // Pharmacol Ther. 2011. — V. 129. -N2. — P. 149−71.
117. Brewin, C.R. A dual representation theory of posttraumatic stress disorder. Text. / C.R.Brewin, T. Dalgleish, S. Joseph // Psychol Rev 1996. — V.103. — N4. — P.670−86.
118. Broadhurst, P.L. The Maudsley reactive and nonreactive strains of rats: a survey. Text. / P.L.Broadhurst // Behav.Genet. 1975. -V.4. — P.299−319.
119. Bromet, E. Risk factors for DSM-III-R posttraumatic stress disorder: findings from the National Comorbidity Survey. Text. /
120. E.Bromet, A. Sonnega, R.C.Kessler // American journal of epidemiology 1998. — N147. — P.353−361.
121. Brown, S. Stress vulnerability and adult alcohol relapse. Text. / S. Brown, P. Vik, T.L.Patterson, I. Grant, M.A.Schuckit // J. Studies Alcohol 1995. — N56. — P.538−545.
122. Brown, T.A. The nature of generalized anxiety disorder and pathological worry: current evidence and conceptual models. Text. / T.A.Brown // Can J Psychiatry. 1997. — V.42. — N8. — P.817−25.
123. Bruce, M. Anxiogenic effects of caffeine in patients with anxiety disorders. Text. / M. Bruce, N. Scott, P. Shine, M. Lader // Arch Gen Psychiatry 1992. — N49. — P.867−869.
124. Bruchas, M.R. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxietylike behavior. Text. / M.R.Bruchas, B.B.Land, J.C.Lemos, C. Chavkin // PLoS One. 2009. — V.4. — N12. — P. e8528.
125. Bruijnzeel, A.W. kappa-Opioid receptor signaling and brain reward function. Text. / A.W.Bruijnzeel // Brain Res Rev. 2009. -V.62. -Nl. — P. 127−46.
126. Brundtland, G.H. Editorials: Mental health in the 21st century Text. / G.H.Brundtland // Bulletin of the World Health Organization -2000. V.78. -P.411.
127. Brtiske, G.R. Two inbred rat strains contrasting for anxiety-related behaviors show similar levels of defensive responses to cat odor. Text. / G.R.Briiske, L.F.Vendruscolo, A. Ramos // Behav Brain Funct. -2007. -N3. -P.17.
128. Buckner, J.D. Specificity of Social Anxiety Disorder as a Risk Factor for Alcohol and Cannabis Dependence. Text. / J.D.Buckner, N.B.Schmidt, A.R.Lang, J.W.Small, R.C.Schlauch, P.M.Lewinsohn // J Psychiatr Res. 2008. — V.42. — N3. — P.230−239.
129. Bush, D.E.A. Self-administration of intravenous amphetamine: effect of nucleus accumbens CCKB receptor activation on fixed-ratioresponding. Text. / D.E.A.Bush, N.J.DeSousa, F.J.Vaccarino // Psychopharmacology 1999. — V.147. — P.331−4.
130. Bystritsky, A. Clinical and Subthreshold Panic Disorder. Text. / A. Bystritsky, L. Kerwin, N. Niv, J.L.Natoli, N. Abrahami, R. Klap, K. Wells, A.S.Young // Depress Anxiety 2010. — V.27. — N4. — P.381−389.
131. Cai, W-H. Postreactivation Glucocorticoids Impair Recallof Established Fear Memory. Text. / W-H.Cai, J. Blundell, J. Han, R.W.Greene, C.M.Powell // J Neurosci 2006. — V.26. — N37. -P.9560−6.
132. Camilleri, M. Treating irritable bowel syndrome: overview, perspective and future therapies. Text. / M. Camilleri // Br. J Pharmacol 2004. — V. 141. — P. 1237−1248.
133. Camilleri, M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Text. / M. Camilleri // Neurogastroenterol Motil. 2008. — V.20. — N9. — P.971−9.
134. Canteras, N.S. Neuroanatomy of anxiety. Text. / N.S.Canteras, L.B.Resstel, L.J.Bertoglio, P. Carobrez Ade, F.S.Guimaraes // Curr. Top. Behav. Neurosci. 2010. — N2. — P.77−96.
135. Cappel, H. Alcohol and tension reduction: a review. Text. / H. Cappel, C.P.Herman // Q J Stud Alcohol 1972. — N33. — P.33−64.
136. Caputo, F. Medications acting on the GABA system in the treatment of alcoholic patients. Text. / F. Caputo, M. Bernardi // Curr Pharm Des. 2010. — V.16. — N19. — P.2118−25.
137. Pat. N20080200367 from 21.08.2008. «Compositions and Methods for Treating Sleep Disorders». Carley, DW. and other.
138. Carlezon, W.A.Jr. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Text. / W.A.Jr.Carlezon, E.H.Chartoff // Nature Protocols 2007. — V.2. -P.2987−2995.
139. Carlson, J.N. Selective enhancement of dopamine utilization in the rat prefrontal cortex by food deprivation. Text. / J.N.Carlson, K.F.Herrick, J.L.Baird, S.D.Glick // Brain Res. 1987. — V.400. — N1. — P.200−203.
140. Carr, B.A. MK-329 blocks the inhibition of alcohol intake by CCK-8. Text. / B.A.Carr, J.D.Ballou, J.C.Snell, P.J.Kulkosky // Peptides. 1993. — V. 14. — N6. — P. 1193−7.
141. Carvajal, C. Emotional behavior in aged. neuropeptide Y (NPY) Y2 knockout mice. Text. / C. Carvajal, Y. Dumont, H. Herzog, R. Quirion // J Mol Neurosci. 2006. — V.28. — N3. — P.239−45.
142. Cascade, E. Use of Benzodiazepines in the Treatment of Anxiety. Text. / E. Cascade, A.H.Kalali // Psychiatry (Edgemont) -2008. V.5. — N9. — P.21−22.
143. Cavaljuga, S. Clomipramine and fluoxetine effects in the234treatment of panic disorder. Text. / S. Cavaljuga, I. Licanin, E. Kapic, D. Potkonjak // Bosn J Basic Med Sci. 2003. — V.3. — N3. — P.27−31.
144. Chambers, M.S. CCK-B antagonists in the control of anxiety and gastric acid secretion. Text. / M.S.Chambers, S.R.Fletcher // In: Progress in Medicinal Chemistry / KingF.D. Oxford: Elsevier Science, 2000. — V.37. — P.45−81.
145. Chambers, M.S. L-708,474: the C5-ciclogexyl analogue if L-365,260, a selective, high-affinity ligand for the CCK-B/gastrin receptor. Text. / M.S.Chambers, S.C.Hobbs, S.R.Fletcher // BioMed. Chem. Lett. 1993. — V.3. — P. 1919−1924.
146. Charney, D.S. Neuroanatomical circuits modulating fear and anxiety behaviors. Text. / D.S.Charney // Acta Psychiatr Scand Suppl -2003b.-N417.-P.38−50.
147. Charney, D.S. The psychobiology of resilience and vulnerability to anxiety disorders: implications for prevention and treatment. Text. / D.S.Charney // Dialogues Clin Neurosci. 2003a. -V.5. — N3. — P.207−221.
148. Chase, T.N. Neostriatal mechanisms in Parkinson’s disease. Text. / T.N.Chase, J.D.Oh, P.J.Blanchet // Neurology 1998. — V.51. — N2 Suppl. — P. S30−5.
149. Chekina, K.S. Benzodiazepine reception in C57BL/6 and BALB/c mice depending on the type of stress factor. Text. / K.S.Chekina, M.A.Yarkova, S.B.Seredenin // Bull Exp Biol Med. -2009. V.148. — N4. — P.606−8.
150. Chen, Y.H. Increased risk of acute myocardial infarction for patients with panic disorder: a nationwide population-based study. Text. / Y.H.Chen, S.Y.Tsai, H.C.Lee, H.C.Lin // Psychosom Med -2009. V.71. — N7. — P.798−804.
151. Chessick, C.A. Azapirones for generalized anxiety disorder. Text. / C.A.Chessick, M.H.Allen, M. Thase, A.B.Batista Miralha da Cunha, F.F.Kapczinski, M.S.de Lima, J.J.dos Santos Souza // Cochrane Database Syst Rev. 2006. — V.3. — P. CD006115.
152. Chopin, P. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus maze. Text. / P. Chopin, M. Briley // Psychopharmacology (Berlin) 1993. — V. 110. — P.409−414.
153. Cole, J.C. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behavior of mice in the elevated plus-maze. Text. / J.C.Cole, R.J.Rodgers // Pharmac. Biochem. Behav. 1995. — N52. — P.473−478.
154. Collins, M.M. Anxiety and depression symptoms in patients with diabetes. Text. / M.M.Collins, P. Corcoran, I.J.Perry // Diabet Med. 2009. — V.6. — N2. — P. 153−61.
155. Copuroglu, C. Acute stress disorder and post-traumatic stress disorder following traumatic amputation. Text. / C. Copuroglu, M. Ozcan, B. Yilmaz, Y. Gorgulu, E. Abay, E. Yalniz // Acta Orthop Belg. 2010. — V.76. — N1. — P.90−3.
156. Cornelis, M.C. Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption. Text. / M.C.Cornelis, A. El-Sohemy, H. Campos // Am J Clin Nutr 2007. -N86. — P.240−244.
157. Correia, D. Trait anxiety and ethanokanxiolysis in high-anxiety mice and no relation to intake behavior in an addiction model. Prog.Neuropsychopharmacol. Text. / D. Correia, A.F.Ribeiro,
158. A.L.Brunialti Godard, R. Boerngen-Lacerda // Biol. Psychiatry. -2009. V.33. — N5. — P.880−888.
159. Cortese, B.M. The role of glutamate in anxiety and related disorders. Text. / B.M.Cortese, K.L.Phan // CNS Spectr. 2005. -V.10.-N10.-P.820−30.
160. Costal 1, B. Anxiolytic effects of CCK-B antagonists Text. /
161. B.Costall, A.M.Domeney, J. Hughes, M.E.Kelly, R.J.Naylor, G.N.Woodruff//Neuropeptides 1991. — V. 19 Suppl. — P.65−73.
162. Covault, J. Allelic and Haplotypic Association of GABRA2 With Alcohol Dependence. Text. / J. Covault, J. Gelernter, V. Hesselbrock, M. Nellissery, H.R.Kranzler // Am J Med Genet В Neuropsychiatr Genet. 2004. — V.129B. — N1. — P.104−9.
163. Crawley, J.N. Cholecystokinin accelerates the rate of habituation to a novel environment. Text. / J.N.Crawley // Pharmacol. Biochem. Behav 1994b. — V.20. — P.23−27.
164. Crawley, J.N. Divergent effects of cholecystokinin, bombesin, and lithium on rat exploratory behaviors. Text. / J.N.Crawley // Peptides. 1983. — V.4. — N4. — P.405−10.
165. Crawley, J.N. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Text. / J.N.Crawley // J. Neurosci. 1992. — V.12. — P.3380−3391.
166. Crawley, J.N. Cholecystokinin-dopamine interactions. Text. / J.N.Crawley // TiPS 1991. — V.12. — N6. — P.232−236.
167. Crawley, J.N. Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Text. / J.N.Crawley // J Neurosci. 1992. — V.12. — N9. -P.3380−91.
168. Crawley, J.N. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Text. / J.N.Crawley, J.K.Belknap, A, Collins // Psychopharmacology (Berl.). 1997. — V.132. — N2. — P. 107−124.
169. Crawley, J.N. Interactions between cholecystokinin and other neurotransmitter systems. Text. / J.N.Crawley // In: Cholecystokinin and Anxiety: From Neuron to Behavior / Eds.: J. Bradwejn, E. Vasar -Austin: RG Landes Company, 1995. P.35−56.
170. Crawley, J.N. Biological actions of cholecystokinin. Text. / J.N.Crawley, R.L.Corwin // Peptides 1994a. — V.15. — P.731−55.
171. Crawley, J.N. Topographical analysis of nucleus accumbenssites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat. Text. / J.N.Crawley, D.W.Hommer, L.R.Skirboll //BrainRes 1985. — V.335. — P.337−41.
172. Crawley, J.N. Neuronal cholecystokinin. Text. / J.N.Crawley, J. J. Vanderhaeghen // Ann. NY Acad. Sei — 1985. — V.448. — P. 1−697.
173. Crespi, F. The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Text. / F. Crespi // Methods Find Exp Clin Pharmacol 1998. — V.20. — P.679−97.
174. Crespi, F. Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism Text. / F. Crespi, M. Corsi, T. England, E. Ratti, D.G.Trist, G. Gaviraghi // Alcohol. 1997. — V.14. — N4. — P.327−332.
175. Crupi, R. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. Text. / R. Crupi, E. Mazzon, A. Marino//J. Pineal Res. 2010. — V.49. — N2. — P.123−129.
176. Cryan, J.F. Assessing antidepressant activity in rodents: recent developments and future needs. Text. / J.F.Cryan, A. Markou, I. Lucki // Trends Pharmacol Sei 2002. — V.23. — P.238−245.
177. Culman, J. Effect of tachykinin receptor inhibition in the brain on cardiovascular and behavioral responses to stress. Text. / J. Culman, S. Klee, C. Ohlendorf, T. Unger // J Pharmacol Exp Ther. -1997. V.280. — N1. — P.238−46.
178. Damsa, C. Current status of brain imaging in anxiety disorders. Text. / C. Damsa, M. Kosel, J. Moussally // Curr.Opin.Psychiatry -2009. -N22. -P.96−110.
179. Das, S. Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health. Text. / S. Das, J.H.O'Keefe // Curr Hypertens Rep. 2008. — V.10. -N5. — P.374−81.
180. Dauge, V. CCK in anxiety and cognitive processes. Text. / V. Dauge, I. Lena // Neurosci Biobehav Rev. 1998. — V.22. — N6. -P.815−25.
181. Davidson, J.R. Pharmacotherapy of generalized anxiety disorder. Text. / J.R.Davidson // J Clin Psychiatry. 2001. — V.62. -N11. -P.46−50.
182. Davidson, J.R. The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Text. / J.R.Davidson, D.L.Hughes, L.K.George, D.G.Blazer // Psychol Med1993. V.23. — N3. — P.709−18.
183. Davidson, J.R.T. Management of Generalized Anxiety Disorder in Primary Care: Identifying the Challenges and Unmet Needs. Text. / J.R.T.Davidson, D.E.Feltner, A. Dugar // Prim Care Companion J Clin Psychiatry. 2010. — V. 12. — N2. — P.PCC.09r00772.
184. Davisson, M. Rules for nomenclature of inbred strains. Text. / M.Davisson. Oxford: Oxford University Press, 1996.
185. De Kloet, E.R. Stress, genes and the mechanism of programming the brain for later life. Text. / E.R.De Kloet, R.M.Sibug, F.M.Helmerhorst, M.V.Schmidt // Neurosci. Biobehav. Rev. 2005. — V.29. — N2. — P.271−281.
186. Degnan, K.A. Temperament and the environment in the etiology of childhood anxiety. Text. / K.A.Degnan, A.N.Almas, N.A.Fox // J Child Psychol Psychiatry 2010. — V.51. — N4. — P.497−517.
187. Text. / J.A.den Boer, B.R.Slaap // Int Clin Psychopharmacol. 1998.- V.13 Suppl 4. P. S25−30.227. den Boer, J.A. The ACTH (4−9) analog ORG 2766 in panic disorder: a preliminary study. Text. / J.A.den Boer, H.G.Westenberg,
188. B.Mastenbroek, J.M.van Ree // Psychopharmacol Bull. 1989. — V.25.- N2. P.204−8.
189. Denys, D. The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidence. Text. / D. Denys, J. Zohar, H.G.M.Westenberg // J Clin Psychiatry. 2004. — N14. — P. 11−17.
190. Derrien, M. Involvement of D2 dopaminergic receptors in the emotional and motivational responses induced by injection of CCK8 in the posterior part of the nucleus accumbens. Text. / M. Derrien,
191. C.Durieux, V. Dauge, B.P.Roques // Brain. Res. 1993. — V.617. -P.181−188.
192. Derrien, M. Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole. Text. / M. Derrien, C. Durieux, P. Roques // Br J Pharmacol 1994. — V. l 11. — N3. — P.956−60.
193. Deschenes, R.J. Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Text. / R.J.Deschenes, L.J.Lorenz, R.S.Haun, B.A.Roos, K.J.Collier, J.E.Dixon // Proc. Natl. Acad. Sci.U.S.A. 1984. — V.81. — P.726−730.
194. DeSousa, N.J. The expression of behavioral sensitization to amphetamine: role of CCKA receptors. Text. / N.J.DeSousa, G.R.Wunderlich, C. De Cabo, F.J.Vaccarino // Pharmacol Biochem
195. Behav- 1999.-V.62.-P.31−7.
196. Di Chiara, G. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. Text. / G. Di Chiara, A. Imperato // J Pharmacol Exp Ther 1988. — N244. — P. 1067−1080.
197. Dohlman, H.G. Model systems for the study of seven-transmembrane-segment receptors. Text. / H.G.Dohlman, J. Thorner, M.G.Caron, R.J.Lefkowitz // Annu Rev Biochem. 1991. — N60. -P.653−88.
198. Donner, J. An association analysis of murine anxiety genes in humans implicates novel candidate genes for anxiety Text. / J. Donner, S. Pirkola, K. Silander, L.l.Kananen, J.D.Terwilliger,
199. Dunn, A.J. Cold restraint alters dopamine metabolism in frontal cortex, nucleus accumbens and neostriatum. Text. / A.J.Dunn, S.E.File// Physiol Behav. 1983. — V.31. — N4. — P.511−513.
200. Dwivedi, Y. Brain-derived neurotrophic factor: role in depression and suicide. Text. / Y. Dwivedi // Neuropsychiatr Dis Treat. 2009. — N5. — P.433¹⁴⁹.
201. Ebner, K. Substance P in stress and anxiety: NK-1 receptorantagonism interacts with key brain areas of the stress circuitry. Text. / K. Ebner, P. Muigg, G. Singewald, N. Singewald // Ann N Y Acad Sei. 2008. — N1144. — P.61−73.
202. Ebner, K. Tachykinin receptors as therapeutic targets in stress-related disorders. Text. / K. Ebner, S.B.Sartori, N. Singewald // Curr Pharm Des. 2009. — V.15. — N14. — P.1647−74.
203. Ebner, K. The role of substance P in stress and anxiety responses. Text. / K. Ebner, N. Singewald // Amino Acids. 2006. -V.31. — N3. — P.251−72.
204. Emson, P.C. Cholecystokinin octapeptide? vesicular localization and calcium dependent release from rat brain in vitro. Text. / P.C.Emson, C.M.Lee, J.F.Rehfeld // Life Sei 1980. — V.26. — P.2157−63.
205. Enoch, M.A. Dimensional Anxiety Mediates Linkage of GABRA2 Haplotypes With Alcoholism. Text. / M.A.Enoch, L. Schwartz, B. Albaugh, M. Virkkunen, D. Goldman // Am J Med Genet B Neuropsychiatr Genet. 2006. — V.141. — N6. — P.599−607.
206. Evans, B.E. Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Text. / B.E.Evans, M.G.Bock, K.E.Rittle, R.M.DiPardo, W.L.Whitter,
207. D.F.Veber, P. S.Anderson, R.M.Freidinger // Proc Natl Acad Sei USA 1986.-V.83.-P.4918−4922.
208. Faris, P.L. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Text. / P.L.Faris, B.R.Komisaruk, L. RWatkins, D.J.Mayer// Science 1983. — V.219. — P.310−312.
209. Fathi, Z. BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. Text. / Z. Fathi, M.H.Corjay, H. Shapira, E. Wada, R. Benya, R. Jensen, J. Viallet,
210. E.A.Sausville, J.F.Battey // J Biol Chem. 1993. — V.268. — N8. -P.5979−84.
211. File, S.E. Contrasting effects of Org 2766 and alpha-MSH onsocial and exploratory behavior in the rat. Text. / S.E.File // Peptides. 1981. — V.2. — N3. — P.255−60.
212. Fink, H. Major biological actions of CCK — a critical evaluation of research findings. Text. / H. Fink, A. Rex, M. Voits, J.P.Voigt//Exp Brain Res 1998. — V. 123. — P.77−83.
213. Flint, A. Aging and Panicogenic Response to Cholecystokinin Tetrapeptide: An Examination of the Cholecystokinin System. Text. / A. Flint, J. Bradwejn, F. Vaccarino, J. RGutkowska, D. Koszycki // Neuropsychopharmacology 2002. — V.27. — P.663−671.
214. Fontani, V. Social anxiety disorder: radio electric asymmetric conveyor brain stimulation versus sertraline. Text. / V. Fontani, P. Mannu, A. Castagna, S. Rinaldi // Patient Prefer Adherence. 2011. -N5. — P.581−6.
215. Fornaro, M. Obsessive-compulsive disorder and related disorders: A comprehensive survey. Text. / M. Fornaro, F. Gabrielli, C. Alabano, S. Fornaro, S. Rizzato, C. Mattei, P. Solano, V. Vinciguerra, P. Fornaro // Ann Gen Psychiatry. 2009. — N18. — P.8−13.
216. Fox, M.A. The inability of CCK to block (or CCK antagonists to substitute for) the stimulus effects of chlordiazepoxide. Text. / M.A.Fox, E.S.Levine, A.L.Riley // Pharmacol Biochem Behav. -2001. -V.69. N1−2. -P.77−84.
217. Frankland, P.W. Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat. Text. /
218. P.W.Frankland, S.A.Josselyn, J. Bradwejn, F.J.Vaccarino, J.S.Yeomans //JNeurosci. 1997. — V.17. — N5. — P.1838−47.
219. Franklin, T.B. Influence of Early Stress on Social Abilities and Serotonergic Functions across Generations in Mice. / T.B.Franklin, N. Linde, H. Russig, B. Thony, I.M.Mansuy // 2011. URL: http://www.ncbi.nlm.nih.gOv/pubmed/21 799 751.
220. Fraser, A.D. Use and abuse of the benzodiazepines. Text. / A.D.Fraser // Ther Drug Monit. 1998. — V.20. — N5. — P.481⁸⁹.
221. Funada, M. Blockade of morphine reward through the activation of kappa-opioid receptors in mice. Text. / M. Funada, T. Suzuki, M. Narita, M. Misawa, H. Nagase // Neuropharmacology. -1993. V.32. -N12. -P.1315−23.
222. Furmark, T. Neurobiological aspects of social anxiety disorder. Text. / T. Furmark // Isr J Psychiatry Relat Sci. 2009. — V.46. — N1. -P.5−12.
223. Furutani, N. Activation of bombesin receptor subtype-3 influences activity of orexin neurons by both direct and indirectpathways. Text. / N. Furutani, M. Hondo, N. Tsujino, T. Sakurai // J Мої Neurosci. -2010. V.42. -Nl. -P.106−11.
224. Fyer, A.J. A direct interview family study of social phobia. Text. / A.J.Fyer, S. Mannuzza, T.F.Chapman, M.R.Liebowitz, D.F.Klein // Arch Gen Psychiatry 1993. — N50. — P.286−93.
225. Gelemter, C.S. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Text. / C.S.Gelemter, T.W.Uhde, P. Cimbolic, D.B.Amkoff, B.J.Vittone, M.E.Tancer // Arch Gen Psychiatry 1991. — N38. — P.938−45.
226. Gerez, M. Amygdalar hyperactivity, a fear-related link between panic disorder and mesiotemporal epilepsy. Text. / M. Gerez, A. Sada, A. Tello // Clin EEG Neurosci. 2011. — V.42. — N1. — P.29−39.
227. Gianoulakis, C. Endogenous opioids and addiction to alcoholand other drugs of abuse. Text. / C. Gianoulakis // Curr Top Med Chem. 2009. — V.9. — N11. — P.999−1015.
228. Glazner, G.W. Effect of bombesin on behaviors associated with ethanol satiation and blood ethanol levels. Text. / G.W.Glazner, R.L.Cannon, P.J.Kulkosky // Alcohol. 1988. — V.5. — N4. — P.325−30.
229. Gloger, S. Treatment of spontaneous panic attacks with chlomipramine. Text. / S. Gloger, L. Grunhaus, B. Birmacher, T. Troudart // Am J Psychiatry. 1981. — V. 138. — N9. — P. 1215−7.
230. Goa, K.L. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Text. / K.L.Goa, A. Ward // Drugs. 1986. — V.32. — N2. — P. 114−129.
231. Goddard, A.W. Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Text. / A.W.Goddard, A. Shekhar, A.F.Whiteman, C.J.McDougle // Drug Discov Today. 2008. — N13. -P.325−332.
232. Goldstein, J.A. Calcium channel blockers in the treatment of panic disorder. Text. / J.A.Goldstein // J.Clin.Psychiatry 1985. -V.46. — P.546.
233. Goltermann, N.R. Newly synthesized cholecystokinin in subcellular fractions of the rat brain. Text. / N.R.Goltermann, K. Stengaard-Pedersen, J.F.Rehfeld, N.J.Christensen // J Neurochem -1981.-V.36.-P.959−65.
234. Green, P.J. The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. Text. / P.J.Green, J. Suls // J Behav Med 1996. — N19. — P. l 11−128.
235. Greenberg, P.E. The economic burden of anxiety disorders in the 1990s. Text. / P.E.Greenberg, T. Sisitsky, R.C.Kessler, S.N.Finkelstein, E.R.Berndt, J.R.Davidson // J Clin Psychiatry 1999. — V.60. -P.427−35.
236. Griebel, G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Text. / G. Griebel // .Pharmacol Ther. 1999. — V.82. -Nl. — P. 1−61.
237. Griebel, G. Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Text. / G. Griebel // Pol J Pharmacol. 1996. — V.48. — N2. — P. 129−36.
238. Griebel, G. Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Text. / G. Griebel, C. Belzung, G. Perrault, D.J.Sanger // Psychopharmacology (Berl). 2000. — V.148. — N2. — P. 164−70.
239. Griebel, G. Non-peptide vasopressin Vlb receptor antagonistsas potential drugs for the treatment of stress-related disorders. Text. / G. Griebel, J. Stemmelin, C.S.Gal, P. Soubrie // Curr Pharm Des. -2005. V. l 1. — N12. — P.1549−59.
240. Gudasheva, T.A. Strategy for the development of dipeptide drugs. Text. / T.A.Gudasheva // Vestn Ross Akad Med Nauk. 2011. — N7. — P.8−16.
241. Gudasheva, T.A. Design of the novel dipeptide neuropsychotropic drug preparations. Text. / T.A.Gudasheva, A.P.Skoldinov // Eksp Klin Farmakol. 2003. — V.66. — N2. — P. 15−9.
242. Gurguis, G.N. Beta-adrenoreceptor coupling to GS protein in alcohol dependence, panic disorder, and patients with both conditions. Text. / G.N.Gurguis, J. Turkka, D.T.George, M. Linnoila // Neuropsychopharmacology. 1997. — V. l6. — N1. — P.69−76.
243. Hahne, W.F. Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Text. / W.F.Hahne, R.T.Jensen, G.F.Lemp, J.D.Gardner // Proc Natl Acad Sci USA.- 1981. V.78. — N10. — P.6304−8.
244. Hall, C.S. Emotional behavior in rat. 1. Defeacation and urination as measures of individual differences in emotionality. Text. / C.S.Hall//J.Compar.Psychol. 1934. — N18. — P.385−403.
245. Hansson, A.C. Neuroplasticity in brain reward circuitry following a history of ethanol dependence. Text. / A.C.Hansson, R. Rimondini, O. Neznanova, W.H.Somme, M. Heilig // Eur J Neurosci -2008.-N27.-P.1912−1922.
246. Harper, E.A. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Text. / E.A.Harper, S.P.Roberts, N.P.Shankley, J.W.Black // Br. J. Pharmac. 1996. -V.l 18. — P.1717−1726.
247. Harrington, G.M. The Har strains of rats: origins and characteristics. Text. / G.M.Harrington // Behav Genet. 1981. -V.l 1. — N5. — P.445−68.
248. Harro, J. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Text. / J. Harro // Naunyn Schmiedebergs Arch Pharmacol 1990a. -V.341. -P.62−7.
249. Harro, J. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies. Text. / J. Harro // Amino Acids. -2006. V.31. -N3.
250. Harro, J. Long-term diazepam treatment produces changes in cholecystokinin receptor binding in rat brain Text. / J. Harro, A. Lang, E. Vasar // Eur J Pharmacol. 19 906. — V. 180. — N1. — P.77−83.
251. Harro, J. Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour? Text. / J. Harro, E. Vasar // Neurosci. Biobehav. Rev. 1991. — V. l5. — P.473−477.
252. Harro, J. CCK in animal and human research on anxiety. Text. / J. Harro, E. Vasar, J. Bradwejn // Trends Pharmacol. Sei. 1993. -V.14. — P.244−249.
253. Haskell, C.F. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Text. / C.F.Haskell, D.O.Kennedy, K.A.Wesnes, A.B.Scholey // Psychopharmacology 2005. — N179. — P.813−825.
254. Hayashi, K. Electroencephalogram abnormalities in panic disorder patients: a study of symptom characteristics and pathology. Text. / K. Hayashi, M. Makino, M. Hashizume, K. Nakano, K. Tsuboi // Biopsychosoc Med. 2010. — V.4. — P.2−9.
255. Hebb, A.L. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Text. / A.L.Hebb, J.F.Poulin, S.P.Roach, R.M.Zacharko, G. Drolet // Prog Neuropsychopharmacol Biol Psychiatry 2005. — N29. — P. 12 251 238.
256. Heberlein, A. Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy. Text. / A. Heberlein, S. Bleich, J. Kornhuber, T. Hillemacher // Hum. Psychopharmacol Clin Exp. 2008. — V.23. — P.171−181.
257. Hedlund, P.B. The 5-HT7 receptor influences stereotypic behavior in a model of obsessive-compulsive disorder. Text. / P.B.Hedlund, J.G.Sutcliffe // Neurosci Lett 2007. — N414. — P.247−251.
258. Heilig, M. The NPY system in stress, anxiety and depression. Text. / M. Heilig // Neuropeptides. 2004. — V.38. — N4. — P.213−24.
259. Heilig, M. Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Text. / M. Heilig, M. Egli, JC. Crabbe, HC. Becker // Addict Biol. 2010. — V. 15. — N2.1. P. 169−84.
260. Heilig, M. A key role for corticotropin-releasing factor in alcohol dependence. Text. / M. Heilig, G.F.Koob // Trends Neurosci -2007. N30. — P.399−406.
261. Hendrie, C.A. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Text. / C.A.Hendrie, J.C.Neill, J.K.Shepherd, C.T.Dourish // Physiol Behav. 1993. — V.54. — N4. — P.689−93.
262. Hensler, J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Text. / J.G.Hensler//Life Sci. -2003. V.72. -N15. -P.1665−82.
263. Hernando, F. The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Text. / F. Hernando, J.A.Fuentes, B.P.Roques, M. Ruiz-Gayo // Eur J Pharmacol. 1994. — V.261. — N3. — P.257−63.
264. Herpfer, I. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. Text. /1.Herpfer, K. Lieb // CNS Drugs. 2005. — V.19. — N4. — P.275−93.
265. Herranz, R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Text. / R. Herranz // Med Res Rev. 2003. -V.23. — N5. — P.559−605.
266. Herrera-Ruiz, D. Current perspectives on established andputative mammalian oligopeptide transporters. Text. / D. Herrera-Ruiz, G.T.Knipp // J Pharm Sei. 2003. — V.92. — P.691−714.
267. Hettema, J.M. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Text. / J.M.Hettema, M.C.Neale, K.S.Kendler // Am J Psychiatry 2001. — V. 158. — P. 1568−78.
268. Hettema, J.M. The structure of genetic and environmental risk factors for anxiety disorders in men and women. Text. / J.M.Hettema, C.A.Prescott, J.M.Myers, M.C.Neale, K.S.Kendler // Arch Gen Psychiatry 2005. — V.62. — P. 182−9.
269. Hewlett, W.A. Clomipramine, clonazepam, and Clonidine treatment of obsessive-compulsive disorder. Text. / W.A.Hewlett, S. Vinogradov, W.S.Agras // J Clin Psychopharmacol. 1992. — V.12. -N6. — P.420−30.
270. Heyman, I. Obsessive-compulsive disorder. Text. / I. Heyman, D. Mataix-Cols, N.A.Fineberg // BMJ 2006. — N333. — P.424−429.
271. Hidalgo, R.B. Social anxiety disorder in review: two decades of progress. Text. / R.B.Hidalgo, S.D.Barnett, J.R.Davidson // Int J Neuropsychopharmacol. 2001. — V.4. — N3. — P.279−298.
272. Hidalgo, R.B. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. Text. / R.B.Hidalgo, L.A.Tupler, J.R.Davidson // J Psychopharmacol. 2007. — V.21. — N8. — P.864−872.
273. Hinkelmann, K. CCK-4: Psychophysiological conditioning elicits features of spontaneous panic attacks. Text. / K. Hinkelmann, A. Yassouridis, R. Mass, H. Tenge, M. Kellner, H. Jahn, K. Wiedemann, K. Wolf//J Psychiatr Res. -2010. -V.44. -N16. P. 1148−53.
274. Hiremath, S.B. Effect of calcium on anxiolytic activity of diazepam and verapamil in rats. Text. / S.B.Hiremath, S. Anand, L.D.Srinivas, M.D.Rashed // Indian J Pharmacol. 2010. — V.42. — N6.- P.406−8.
275. Hjelmstad, G.O. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. Text. / G.O.Hjelmstad, H.L.Fields // J Neurophysiol. 2003. — V.89. — N5. — P.2389−95.
276. Hofmann, S.G. Psychophysiological differences between subgroups of social phobia. Text. / S.G.Hofmann, M.G.Newman, A. Ehlers, W.T.Roth // J Abnorm Psychol 1995. — V. 104. — N1. -P.224−31.
277. Hokfelt, T. Distribution patterns of CCK and CCK mRNA in some neuronal and non-neuronal tissues. Text. / T. Hokfelt, R. Cotes,
278. M.Schalling, S. Ceccatelli, M. Pelto-Huikko, H. Persson, M.J.Villar // Neuropeptides 1991. — V. 19. — P.31−43.
279. Hokfelt, T. Neuronal Cholecystokinin. Text. / T. Hokfelt, J.J.Vanderhaeghen, J.N.Crawley // New York Academy of Sciences -1985. -P.255−274.
280. Holland, K.L. Infusion of CCK-A receptor mRNA antisense oligodeoxynucleotides inhibits lordosis behavior. Text. / K.L.Holland, P. Popper, P.E.Micevych // Physiol Behav. 1997. -V.62. — N3. — P.537−43.
281. Hollander, E. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. Text. / E. Hollander, A. Allen, M. Steiner // J Clin Psychiatry. 2003. — N64. -P.1113−1121.
282. Holmes, A. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Text. / A. Holmes, M. Heilig, N.M.Rupniak, T. Steckler, G. Griebel // Trends Pharmacol Sei. 2003. — V.24. -Nil.- P.580−8.
283. Holmes, A. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze. Text. / A. Holmes, J.W.Kinney, C.C.Wrenn // Neuropsychopharmacology. 2003. — N28. — P. 1031−1044.
284. Holmes, A. Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Text. / A. Holmes, S. Parmigiani, P.F.Ferrari, P. Palanza, R.J.Rodgers // Physiol, and Behav. 2000. -V.71. — P.509−516.
285. Holmes, A. Evaluation of an anxiety-related phenotype in galanin overexpressing transgenic mice. Text. / A. Holmes, R.J.Yang, J.N.Crawley // J Mol Neurosci. 2002. — N18. — P.151−165.
286. Horwell, D.C. Development of CCK-B antagonists. Text. /
287. D.C.Horwell // Neuropeptides 1991. — V.19. — P.57−64.
288. Hosing, VG. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. Text. / VG. Hosing, A. Schirmacher, G. Kuhlenbaumer, C. Freitag, P. Sand, JacobSchlesiger C // J.Neural. Transm. 2004. — N68. — P. 147−56.
289. Hosli, E. Binding of cholecystokinin, bombesin and muscarine to neurons and astrocytes in explant cultures of rat central nervous system: autoradiographic and immunohistochemical studies. Text. /
290. E.Hosli, L. Hosli//Neuroscience. 1994. — V.61. -Nl. — P.63−72.
291. Hosli, L. Electrophysiological evidence for the presence of receptors for cholecystokinin and bombesin on cultured astrocytes of rat central nervous system. Text. / L. Hosli, E. Hosli, T. Winter,
292. H.Kaser // Neurosci Lett. 1993. — V. 163. — N2. — P. 145−7.
293. Hovatta, I. Molecular genetics of anxiety in mice and men. Text. / I. Hovatta, C. Barlow // Ann. Med. 2008. — V.40. — N2. -P.92−109.
294. Hovatta, I. Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Text. / I. Hovatta, R.S.Tennant, R. Helton // Nature. -2005. V.438. — N7068. — P.662−666.
295. Huang, C.J. Prevalence and incidence of anxiety disorders in diabetic patients: a national population-based cohort study. Text. / C.J.Huang, H.C.Chiu, M.H.Lee, S.Y.Wang // Gen Hosp Psychiatry. -2011. V.33. — N1. — P.8−15.
296. Huang, M.F. Moderators and mediators among panic, agoraphobia symptoms, and suicidal ideation in patients with panic disorder. Text. / M.F.Huang, C.F.Yen, F.W.Lung // Compr Psychiatry. 2010. — V.51. — N3. — P.243−9.
297. Huang, S.C. Multiple affinity states of different cholecystokinin receptors. Text. / S.C.Huang, K.P.Fortune, S.A.Wank, A.S.Kopin, J.D.Gardner // J. Biol. Chem. 1994. — V.269. — N42. — P.26 121−26 126.
298. Hughes, J. Development of a class of selective cholecystokinin type B receptor antagonists having poternt anxiolytic activity Text. / J. Hughes, P. Boden, B. Costall // PNAS USA 1990. — V.87. — P.67 286 732.
299. Hunnerkopf, R. Interaction between BDNF Val66Met and dopamine transporter gene variation influences anxiety-related traits. Text. / R. Hunnerkopf, A. Strobel, L. Gutknecht, B. Brocke, K.P.Lesch //Neuropsychopharmacology 2007. — V.32. — P.2552−2560.
300. Huppi, K. Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. Text. / K. Huppi, D. Siwarski, J.R.Pisegna, S. Wank // Genomics. 1995. — V.25. — N3. — P.727−9.
301. Hurwitz, I. Stress and pain responses in rats lacking CCK1 receptors. Text. / I. Hurwitz, O. Malkesman, Y. Stern, M. Schroeder, Y. Lavi-Avnon, M. Shayit, Y. Shavit, G. Wolf, R. Yirmiya, A. Weiler // Peptides. 2006. — V.27. — N6. — P. 1483−9.
302. Ivy, A.C. A gormone mechanism for gallbladder contraction and evacuation. Text. / A.C.Ivy, E. Oldberg // Am. J. Physiol. 1928. — V.86. -P.599−613.
303. Janet, P. Les Obsessions et la Psychastenia. Text. / P. Janet- Eds.: F.Alcan. Paris., 1903.
304. Jefferson, J.M. Social anxiety disorder: more than just a little shyness. Text. / J.M.Jefferson // Primary Care Companion. J.Clin.Psychiatry. 2001. — V.3. — N1. — P.4−9.
305. Jobson, K.O. International Psychopharmacology Algorithm Project Report. Text. / K.O.Jobson, W.Z.Potter // Psychopharmacol Bull. 1995. — V.31. — N3. — P.457−9, 491−500.
306. Johnson, N. Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice. Text. / N. Johnson, R.J.Rodgers // Psychopharmacology -1996. V.124. -P.355−64.
307. Johnson, P.L. Orexin 1 receptors are a novel target to modulate panic responses and the panic brain network. Text. / P.L.Johnson, B.C.Samuels, S.D.Fitz, L.M.Federici, N. Hammes, M.C.Early,
308. W.Traitt, C.A.Lowry, A. Shekhar // Physiol Behav. 2012. -P.http://www.ncbi.nlm.nih.gov/pubmed/22 554 617.
309. Johnson, P.L. A key role for orexin in panic anxiety. Text. / P.L.Johnson, W. Truitt, S.D.Fitz, P.E.Minick, A. Dietrich, S. Sanghani, L. Traskman-Bendz, A. W. Goddard, L. Brundin, A. Shekhar // Nat Med. -2010.-V.16.-N1.-P.111−5.
310. Johnson, W.D. The TM2 6' position of GABA (A) receptors mediates alcohol inhibition. Text. / W.D.Johnson, R.J.Howard, J.R.Trudell, R.A.Harris // J Pharmacol Exp Ther. 2012. — V.340. -N2. — P.445−56.
311. Jones, E.G. The origins of cortical interneurons: mouse versus monkey and human. Text. / E.G.Jones // Cereb. Cortex. 2009. -V.19. — N9. — P.1953−1956.
312. Joseph, M. Glucocorticoid Release and Memory Consolidation in Men and Women. Text. / M. Joseph, L.C.Andreano // Psychological Science 2006. — V.17. — N6. — P.466−70.
313. Joshi, S.K. kappa -opioid receptor agonists modulate visceral nociception at a novel, peripheral site of action. Text. / S.K.Joshi, X. Su, F. Porreca, G.F.Gebhart // J Neurosci. 2000. — V.20. — N15. -P.5874−9.
314. Jupp, B. Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin! receptors. Text. / B. Jupp, E. Krstew, G. Dezsi, A.J.Lawrence
315. Br J Pharmacol. 2011. — V. 162. — N4. — P.880−9.
316. Kalivas, P.W. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Text. / P.W.Kalivas, J. Stewart // Brain Res Rev 1991. — V.16. -P.223−44.
317. Kalueff, A.V. Role of GAB A in Anxiety and Depression. Text. / A.V.Kalueff, D.J.Nutt // Depress Anxiety. 2007a. — V.24. -N7. — P.495−517.
318. Kalueff, A.V. What’s wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Text. / A.V.Kalueff, M. Wheaton, D.L.Murphy // Behav. Brain Res. 2007b. — V.179. — N1. — P.1−18.
319. Kamp, E.H. Quantitative assessment and characterization of ' visceral nociception and hyperalgesia in mice. Text. / E.H.Kamp, R.C.3rdJones, S.R.Tillman, G.F.Gebhart // Am J Physiol Gastrointest Liver Physiol. 2003. — V.284. — N3. — P. G434−44.
320. Kania, B.F. Centrally administered PD 140.548 N-methyl-D-glucamine prevents the autonomic responses to duodenal pain in sheep. Text. / B.F.Kania, K. Kania, K. Romanowicz, D. Tomaszewska,
321. V.Sutiak, D. Wronska-Fortuna // Res Vet Sci. 2006. — V.81. — N1. -P.109−18.
322. Kapoor, A. Testosterone is involved in mediating the effects of prenatal stress in male guinea pig offspring. Text. / A. Kapoor, S.J.Matthews // J Physiol. 2011. — V.589. — NPt 3. — P.755−766.
323. Kariya, K. Systemic administration of CCK-8S, but not CCK-4, enhances dopamine turnover in the posterior nucleus accumbens: a microdialysis study in freely moving rats. Text. / K. Kariya // Brain Res 1994.-V.657.-P.1−6.
324. Katerndahl, D.A. The association between panic disorder and coronary artery disease among primary care patients presenting with chest pain: an updated literature review. Text. / D.A.Katerndahl // J Clin Psychiatry 2008. — V.10. — N4. — P.276−85.
325. Keller, M.B. Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials. Text. / M.B.Keller // J Clin Psychiatry 2000. — V.61. — N12. — P.896−908.
326. Kenakin, T. Agonist-receptor efficacy. II: Agonist trafficking of receptor signals. Text. / T. Kenakin // Trends Pharmacol. Sci. 1995. — V.16. -P.232−238.
327. Kendler, K.S. The genetic epidemiology of phobias in women: the interrelationship of agoraphobia, social phobia, situation phobia and simple phobia. Text. / K.S.Kendler, M.C.Neale, R.C.Kessler // Arch GenPsychiatry 1992. — N49. — P.273−81.
328. Kessler, R.C. Rethinking the duration requirement for generalized anxiety disorder: evidence from National Comorbidity Survey Replication. Text. / R.C.Kessler, N. Brandeburg, M. Lane // Psycol Med 2005. — V.35. — P.1073−82.
329. Kessler, R.C. The epide-miology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Text. / R.C.Kessler, W.T.Chiu, N.R.Ji, A.M.Ruscio, K. Shear, E.E.Walters // Arch Gen Psychiatry 2006. — V.63. — P.415−24.
330. Kessler, R.C. Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Text. / R.C.Kessler, K.A.McGonagle, S. Zhao // Arch.Gen. Psychiatry 1994a. — V.51. — P.8−19.
331. Kew, J.N. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Text. / J.N.Kew, J.A.Kemp // Psychopharmacology (Berl). 2005. — V. 179. — N1. — P.4−29.
332. Kiefer, F. Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency? Text. / F. Kiefer, M. Horntrich, H. Jahn, K. Wiedemann // Psychopharmacology (Berl). 2002. — V.162. — N4. -P.433−7.
333. Kim, S.J. Obsessive-compulsive disorder, factor-analyzed symptom dimensions and serotonin transporter polymorphism. Text. / S.J.Kim, H.S.Lee, C.H.Kim // Neuropsychobiology 2005. — N52.1. P.176−182.
334. Klein, D.F. Anxiety reconceptualized. Text. / D.F.Klein // Compr Psychiatry 1980. — V.21. — N6. — P.411−27.
335. Klein, E. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine. Text. / E. Klein, V. Colin, J. Stolk, R.H.Lenox // Am J Psychiatry. 1994. -V. 151. -N12. — P. 1760−6.
336. Klein, E. controlled study of verapamil for treatment of panic disorder. Text. / E. Klein, T.W.Uhde // Am.J.Psychiatry 1988. -V.145. — P.431−44.
337. Klerman, G.L. Panic attacks in the community. Social morbidity and health care utilization. Text. / G.L.Klerman, M.M.Weissman, R. Ouellette, J. Johnson, S. Greenwald // JAMA -1991. V.256. — N6. — P.742−6.
338. Kliethemes, C.L. Anxiety-like behaviors following chronic ethanol exposure. Text. / C.L.Kliethemes // Neurosci Biobehav Rev. 2005. — V.28. — N8. — P.837−50.
339. Knapp, D. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and alcohol withdrawal. Text. / D. Knapp, D. Overstreet, G. Breese // Alcohol Clin Exp Res 2007a. — N31. — P.582−595.
340. Knapp, D. SB242084, flumazenil, and CRA1000 block alcohol withdrawal-induced anxiety. Text. / D. Knapp, D. Overstreet, S. Moy, G. Breese // Alcohol 2004. — N32. — P. 101−111.
341. Knoll, A.T. Dynorphin, stress, and depression. Text. / A.T.Knoll, W.A.Jr.Carlezon // Brain Res. 2010. — N1314. — P.56−73.
342. Knoll, A.T. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. Text. / A.T.Knoll, E.G.Meloni, J.B.Thomas, F.I.Carroll, W.A.Jr.Carlezon // J Pharmacol Exp Ther. 2007. — V.323. — N3. — P.838−45.
343. Knoll, A.T. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Text. / A.T.Knoll, J.W.Muschamp, S.E.Sillivan, D. Ferguson // Biol Psychiatry. 2011. — V.70. — N5. — P.425−33.
344. Ko, G.N. Panic-induced elevation of plasma MHPG levels in phobic-anxious patients. Effects of Clonidine and imipramine. Text. / G.N.Ko, J.D.Elsworth, R.H.Roth, B.G.Rifkin, H. Leigh,
345. D.Jr.Redmond // Arch Gen Psychiatry. 1983. — V.40. — N4. — P.425−30.
346. Kodish, I. Pharmacotherapy for anxiety disorders in children and adolescents. Text. / I. Kodish, C. Rockhill, C. Varley // Dialogues Clin Neurosci. 2011. — V. 13. — N4. — P.439−452.
347. Koefoed, P. Gene variations in the cholecystokinin system in patients with panic disorder. / P. Koefoed, D.P.Woldbye, T.O.Hansen,
348. E.S.Hansen, G.M.Knudsen, T.G.Bolwig, J.F.Rehfeld // Psychiatr Genet. 2010. — P.20. — URL: http://www.ncbi.nlm.nih.gov/pubmed/20 023 595.
349. Koen, N. Pharmacotherapy of anxiety disorders: a critical review. Text. / N. Koen, D.J.Stein // Dialogues Clin Neurosci. 2011.- V.13. -N4. -P.423−437.
350. Kofoed, L. Alcoholism and drug abuse in patients with PTSD. Text. / L. Kofoed, M.J.Friedman, R. Peck // Psychiat Q 1993. — N64.- P.151−171.
351. Koike, H. Behavioral abnormality and pharmacologic response in socialisolation-reared mice. Text. / H. Koike, D. Ibi, H. Mizoguchi, T. Nagai, A. Nitta, K. Takuma, T. Nabeshima, Y. Yoneda, K. Yamada // Behav. Brain Res. 2009. — V.202. — N1. — P. 114−121.
352. Koks, S. BOC-CCK-4, CCK-B receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Text. / S. Koks, A. Soosaar, V. Voikar, M. Bourin, E. Vasar // Neuropeptides -1999. V.33. -P.63−9.
353. Kolik, L. The pattern of alcohol drinking in Russian Maudsley
354. Reactive and Maudsley Non-Reactive rats Text. / L. Kolik // Abstract book from 4th Morzine meeting «Pharmacology, Biochemistry and Behavior». Morzine, France, 2000. — P. 18.
355. Kolik, L. Psychopharmacological study of the novel dipeptide anxiolytic GB-115 in animals with different phenotypes of emotional stress reaction. Text. / L. Kolik, T. Gudasheva, S. Seredenin // Int. J. Neuropsychopharmacol. 2008. — V. l 1. — N1. — P.274.
356. Kolik, L.G. Dipeptide anxiolytic GB-115: new receptor targets Text. / L.G.Kolik, T.A.Gudasheva, S.B.Seredenin // Eur. Neuropsychopharmacology. 2011. — V.21. — NSuppl.2. — P. S 146−147.
357. Koob, G.F. Alcoholism: Allostasis and beyond. Text. / G.F.Koob // Alcohol Clin Exp Res 2003. — N27. — P.232−243.
358. Koob, G.F. Addiction and the brain antireward system. Text. / G.F.Koob, M. Le Moal // Annu Rev Psychol 2008. — N59, — P.29−53.
359. Kopin, A.S. CCK receptor polymorphisms: an illustration of emerging themes in pharmacogenomics. Text. / A.S.Kopin, E.W.Mcbride, K. Schaffer, M. Beinborn // Trends Pharmacol. Sei. -2000. V.21. -P.346−353.
360. Kopp, C. Effects of melatonin on neophobic responses in different strains of mice. Text. / C. Kopp, E. Vogel, M.C.Rettori, P. Delagrange, B. Guardiola-Lemaitre, R. Misslin // Pharmacol- Biochem Behav. 1999. — V.63. — N4. — P.521−6.
361. Koprowska, M. Age-related changes in fear behavior and regional brain monoamines distribution in rats Text. / M. Koprowska, M. Krotewicz, A. Romaniuk, M. Strzelczuk // Acta Neurobiol Exp (Wars) 2004. — V.64. — N2. — P. 131−42.
362. Koran, L.M. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Text. / L.M.Koran, G.L.Hanna, E. Hollander, G. Nestadt, H.B.Simpson // Am J Psychiatry 2007. -N164. -P.5−53.
363. Kotlinska, J. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Text. / J. Kotlinska, M. Bochenski // Eur J Pharmacol. 2008. — V.598. — N1−3. — P.57−63.
364. Kravtsova, O. Investigation of the effects of mexidol in escapable and inescapable emotional stress in inbred BALB/C and C57BL/6 mice. Text. / O. Kravtsova, T.A.Voronina, A.K.Sariev // Eksp Klin Farmakol. 2004. — V.67. — N6. — P.8−11.
365. Kryzhanovskii, G.N. Effect of diazepam and nicotinamide on convulsive activity of various types. Text. / G.N.Kryzhanovskii,
366. A.A.Shandra // Farmakol Toksikol. 1985. — V.48. — N4. — P.21−5.
367. Kulkosky, P.J. Bombesin and ceruletide-induced grooming and inhibition of ingestion in the rat. Text. / P.J.Kulkosky // Ann N Y Acad Sci. 1988. — N525. — P.201−18.
368. Kulkosky, P.J. Cholecystokinin-induced satiation with ethanol: effects of lighting cycle and limited access procedures. Text. / P.J.Kulkosky, M.A.Foderaro, S.L.Sandoval, S.S.Cesar, D.A.Marrinan // Alcohol. 1991. — V.8. — N3. — P.223−7.
369. Kulkosky, P.J. Bombesin and litorin inhibit ethanol intake. Text. / P.J.Kulkosky, M. Roque, M.R.Sanchez // Peptides. 1985. -V.6. — NSuppl 2. — P. 103−5.
370. Kulkosky, P.J. Characteristics of bombesin-induced inhibition of intake of ethanol. Text. / P.J.Kulkosky, M.R.Sanchez, N. Chiu, G.W.Glazner // Neuropharmacology. 1987. — V.26. — N8. — P.1211−6.
371. Kulkosky, P.J. Bombesin reduces alcohol choice in nutritive expectancy and limited-access procedures. Text. / P.J.Kulkosky, M.R.Sanchez, D.A.Marrinan // Alcohol. 1992. — V.9. — N2. — P. 1237.
372. Kulkosky, P.J. Interaction of TRH and CCK in the satiation of alcohol intake. Text. / P.J.Kulkosky, V.J.Wise, S.S.Brandt, K.J.Chavez// Physiol Behav. 2004. — V.82. — N1. — P.53−6.
373. Kurrikoff, K. Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin. Text. / K. Kurrikoff, J. Inno, T. Matsui, E. Vasar // Eur J Neurosci. 2008. -V.27. — N8. — P.2147−55.
374. Kutz, A. Evaluating Emotional Sensitivity and Tolerance Factors in the Prediction of Panic-Relevant Responding to a Biological Challenge. Text. / A. Kutz, E. Marshall, A. Bernstein, M.J.Zvolensky // J Anxiety Disord. 2010. — V.24. — N1. — P. 16−22.
375. LaLonde, C.D. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and metaanalysis. Text. / C.D.LaLonde, R.J.Van Lieshout // J Clin Psychopharmacol. 2011. — V.31. — N3. — P.326−33.
376. Lanca, A.J. Cholecystokinergic innervation of nucleus accumbens subregions. Text. / A.J.Lanca, C. de Cabo, A.I.Arifuzzaman, F.J.Vaccarino // Peptides 1998. — V.19. — P.859−68.
377. Landgraf, R. Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Text. / R. Landgraf, M.S.Kessler, M. Bunck // Neurosci. Biobehav. Rev. 2007. — V.31. — N1. — P.89−102.
378. LaPorta, J.L. Refining psychiatric genetics: from 'mouse psychiatry' to understanding complex human disorders. Text. / J.L.LaPorta, R.F.Ren-Patterson, D.L.Murphy, A.V.Kalueff // Behav Pharmacol. 2008. — V.19. — N5−6. — P.377−384.
379. Lauria-Horner, B.A. Pregabalin: a new anxiolytic. Text. / B.A.Lauria-Horner, R.B.Pohl // Expert Opin Investig Drugs 2003. -V.12. — N4. — P.663−72.
380. Le Bars, D. Animal Models of Nociception. Text. / D. Le Bars,
381. M.Gozariu, S.W.Cadden // Pharmacol. Rev. 2001. — N53. — P.597−652.
382. LeDoux, J. The emotional brain, fear, and the amygdala. Text. / J. LeDoux // Cell Mol. Neurobiol 2003. — N23. — P.727−738.
383. Lee, R.S. Chronic corticosterone exposure increases expression and decreases deoxyribonucleic acid methylation of Fkbp5 in mice. Text. / R.S.Lee, K.L.Tamashiro, X. Yang // Endocrinology. 2010. -V.151. — N9. — P.4332−4343,
384. Lee, S.Y. Cholecystokinin: A multi-functional molecular switch of neuronal circuits. Text. / S.Y.Lee, I. Soltesz // J Neurosci. -2011. V.31. — N30. — P. 10 993−11 002.
385. Lee, S-H. Requirement for CB1 but not GABAB receptors in the cholecystokinin mediated inhibition of GABA release from cholecystokinin expressing basket cells. Text. / S-H.Lee, I. Soltesz // J Physiol 2011. — V.589. — N4. — P.891−902.
386. Lee, Y.M. The human brain cholecystokinin- B/gastrin receptor. Cloning and characterization. Text. / Y.M.Lee, M. Beinborn, E.W.Mcbride, M. Lu, J.R.Kolakowski, A.S.Kopin // J. Biol. Chem. 1993. — V.268. — P.8164−8169.
387. Lehmann, F. New molecular targets for treatment of peptic ulcer disease. Text. / F. Lehmann, P. Hildebrand, C. Beglinger // Drugs. 2003. — V.63. — N17. — P. 1785−97.
388. Leinonen, E. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. Text. / E. Leinonen, U. Lepola, H. Koponen, J. Turtonen, A. Wade, H. Lehto // J Psychiatry Neurosci. 2000. — V.25. — N1. — P.24−32.
389. Lenze, E.J. A lifespan view of anxiety disorders. Text. / E.J.Lenze, J.L.Wetherell // Dialogues Clin Neurosci. 2011. — V. 13. -N4. — P.381−99.
390. Lepicard, E.M. Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Text. / E.M.Lepicard, C. Joubert, I. Hagneau, F. Perez-Diaz,
391. G.Chapouthier // Pharmacol Biochem Behav. 2000. — V.67. — N4. -P.739−748.
392. Lepine, J.P. The epidemiology of anxiety disorders: prevalence and societal costs. Text. / J.P.Lepine // J Clin Psychiatry 2002. -V.63. -NSuppl 14. -P.4−8.
393. Leshner, A.I. Drugs of abuse and the brain. Text. / A.I.Leshner, G.F.Koob // Proc Assoc Am Physicians 1999. — V. l 11. — P.99−108.
394. Lesscher, H.M. Amygdala protein kinase C epsilon regulates corticotropin-releasing factor and anxiety-like behavior. Text. /
395. H.M.Lesscher, T. Mcmahon, A.W.Lasek // Genes Brain Behav. -2008. V.7. — N3. — P.323−333.
396. Li, D. Toward an integrative understanding of social phobia. Text. / D. Li, P. Chokka, P. Tibbo // J Psychiatry Neurosci. 2001. -V.26.-N3.-P. 190−202.
397. Licata, S.C. Abuse and dependence liability of benzodiazepine-type drugs: GABA (A) receptor modulation and beyond. Text. / S.C.Licata, J.K.Rowlett // Pharmacol Biochem Behav. 2008. — V.90.- N1. P.74−89.
398. Liddle, R.A. Cholecystokinin cells. Text. / R.A.Liddle // Annu. Rev. Physiol. 1997. — V.59. — P.221−242.
399. Lieb, R. The epidemiology of generalized anxiety disorder in Europe. Text. / R. Lieb, E. Becker, C. Altamura // Eur Neuropsychopharmacol 2005. — V.15. — N4. — P.445−52.
400. Liebowitz, M.R. MAOIs: impact on social behavior. Text. / M.R.Liebowitz, R. Campeas, E. Hollander // Psychiatry Res 1987. -V.22. — N1. — P.89−90.
401. Liebowitz, M.R. Phenelzine versus atenolol in social phobia. A placebo-controlled comparison. Text. / M.R.Liebowitz, F. Schneier, R. Campeas, E. Hollander, J. Hatterer, A. Fyer // Arch Gen Psychiatry -1992.-N49.-P.290−300.
402. Lightowler, S. Anxiolytic-like effect of paroxetine in a rat social interaction test. Text. / S. Lightowler, G.A.Kennet, I.J.Williamson, T.P.Blackburn, I.F.Tulloch // Pharmacol Biochem Behav 1994. — N49. — P.281−5.
403. Lignon, M.F. Cholecystokinin increases intracellular Ca2+ concentration in the human JARKAT T lymphocyte cell line. Text. / M.F.Lignon, N. Bernard, J. Martinez // Eur. J. Pharmacol 1993. -V.245. — P.241−246.
404. Lin, J.H. Improved oral absorption of L-365, 260, a poorly soluble drag. Text. / J.H.Lin, D.E.Storey, I.W.Chen, X. Xu // Biopharm drag dispos. 1996. — V.17. — N1. — P. l-15.
405. Lister, R.G. The use of a plus-maze to measure anxiety in the mouse. Text. / R.G.Lister // Psychopharmacology 1987. — V.92. -P.180−185.
406. Longo, L.P. Addiction, pt 1: benzodiazepines: side effects, abuse risk and alternatives. Text. / L.P.Longo, B. Johnson // Am Fam Physician. 2000. — V.61. — N7. — P.2121−2128.
407. Lotti, V.J. A new potent and selective nonpeptide gastrinantagonist and brain cholecystokinin receptor (CCKB) ligand: L-365,260. Text. / V.J.Lotti, R.S.Chang // Eur. J. Pharmacol. 1989. -V.162. — P.273−280.
408. Lovick, T.A. Pro-nociceptive action of cholecystokinin in the periaqueductal grey: a role in neuropathic and anxiety-induced hyperalgesic states. Text. / T.A.Lovick // Neurosci Biobehav Rev. -2008. V.32. — N4. — P.852−62.
409. Lum, M. Probable interaction of sodium divalproex with benzodiazepines. Text. / M. Lum, R. Fontaine, R. Elie, A. Ontiveros // Prog Neuropsychopharmacol Biol Psychiatry. 1991. — V.15. — N2. -P.269−73.
410. Lydiard, R.B. Neuropeptides and anxiety: focus on cholecystokinin. Text. / R.B.Lydiard // Clin Chem. 1994. — V.40. -N2. — P.315−8.
411. Lydiard, R.B. Anxiety and the irritable bowel syndrome: psychiatric, medical, or both? Text. / R.B.Lydiard // J Clin Psychiatry. 1997. — V.58. — NSuppl.3. — P.51−8.
412. Lydiard, R.B. CSF cholecystokinin concentrations in patients with panic disorders and in normal comparison subjects. Text. / R.B.Lydiard, J.C.Ballenger, M.T.Laraia, M.D.Fossey, M.C.Beinfeld // Am J. Psychiatry 1992. — V.149. — P.691−693.
413. Mague, S.D. Antidepressant-like effects of K-opioid receptor antagonists in the forced swim test in rats. Text. / S.D.Mague,
414. A.M.Pliakas, M.S.Todtenkopf, H.C.Tomasiewicz, Y. Zhang, W.C.Jr.Stevens, R.M.Jones, P. S.Portoghese, W.A.Jr.Carlezon // J Pharmacol Exp Ther 2003. — N305. — P.323−330.
415. Maldonado, R. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK-B antagonist PD-134,308. Text. / R. Maldonado, O. Valverde,
416. B.Ducos, A. GBlommaert, M. CFornie-Zalusci, B.P.Roques // Pr. J. Pharmacol, 1995. — V. l 14. — P.1031−1039.
417. Malesci, A. CCK-1 receptor blockade for treatment of biliary colic: a pilot study. Text. / A. Malesci, R. Pezzilli, M. D'Amato, L. Rovati // Aliment. Pharmacol Ther 2003. — V. l8. — P.333−337.
418. Mancini, C. A high-risk pilot study of the children of adults with social phobia. Text. / C. Mancini, M. van Ameringen, P. Szatmari, C. Fugere, M. Boyle // J Am Acad Child Adolesc Psychiatry 1996. -N35. -P.1511−7.
419. Maner, J.K. Submitting to Defeat: Social Anxiety, Dominance Threat, and Decrements in Testosterone. Text. / J.K.Maner, S.L.Miller, N.B.Schmidt, L.A.Eckel // Psychol Sci. 2008. — V. l9. -N8. — P.764−768.
420. Mangiavacchi, S. Long-term behavioral and neurochemical effects of chronic stress exposure in rats. Text. / S. Mangiavacchi, F. Masi, S. Scheggi, B. Leggio, M.G.De Montis, C. Gambarana // J Neurochem. 2001. — V.79. — N6. — P. l 113−21.
421. Marazziti, D. Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia. Text. / D. Marazziti, M. Carlini, L. Dell'osso // Curr Top Med Chem. 2012. — V. 12. — N4. -P.238−53.
422. Margolis, E.B. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Text. / E.B.Margolis, H. Lock, V.I.Chefer, T.S.Shippenberg, GO. Hjelmstad, H.L.Fields // Proc Natl Acad Sci USA 2006. — N103. — P.2938−2942.
423. Margoob, M.A. Serotonin transporter gene polymorphism and psychiatric disorders: Is there a link? Text. / M.A.Margoob, D. Mushtaq // Indian J Psychiatry. 2011. — V.53. — N4. — P.289−99.
424. Marinelli, P.W. A microdialysis profile of dynorphin A (l-8) release in the rat nucleus accumbens following alcohol administration. Text. / P.W.Marinelli, M. Lam, L. Bai, R. Quirion, C. Gianoulakis // Alcohol Clin Exp Res. 2006. — N30. — P.982−990.
425. Markou, A. Desmethylimipramine attenuates cocaine withdrawal in rats. Text. / A. Markou, R.L.Hauger, G.F.Koob // Psychopharmacol 1992. — N109. — P.305−314.
426. Maron, E. Advances in molecular genetics of panic disorder. Text. / E. Maron, J.M.Hettema, J. Shlik // Mol Psychiatry 2010. -V.15. — P.681−701.
427. Marshall, F.H. Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. Text. / F.H.Marshall, S. Barnes, J. Hughes,
428. G.N.Woodruff, J.C.Hunter // J Neurochem 1991. — V.56. — P.917−22.
429. Martin, W.R. History and development of mixed opioid agonists, partial agonists and antagonists. Text. / W.R.Martin // Br J Clin Pharmacol. 1979. — V.7. — NSuppl 3. — P.273S-279S.
430. Mathew, S.J. Open-label trial of riluzole in generalized anxiety disorder. Text. / S.J.Mathew, J.M.Amiel, J.D.Coplan, H.A.Fitterling,
431. H.A.Sackeim, J.M.Gorman // Am J Psychiatry. 2005. — V.162. -N12.-P.2379−81.
432. Mathew, S.J. Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Text. / S.J.Mathew, R.B.Price, X. Mao, E.L.Smith, J.D.Coplan, D.S.Charney, D.C.Shungu // Biol Psychiatry. 2008. — V.63. — N9. — P.891−8.
433. Mathiasen, L.S. Strain- and model-dependent effects of chlordiazepoxide, L-838,417 and Zolpidem on anxiety-like behaviours in laboratory mice. Text. / L.S.Mathiasen, N.R.Mirza, R.J.Rodgers // Pharmacol. Biochem. Behav. 2008. — V.90. — N1. — P. 19−36.
434. Mattioli, L. Evaluation of Rhodiola rosea L. extract on affective and physical signs of nicotine withdrawal in mice. Text. / L. Mattioli, M. Perfumi // J. Psychopharmacol. 2011. — V.25. — N3. — P.402−410.
435. Maunder, R.G. Panic disorder associated with gastrointestinal disease: review and hypotheses. Text. / R.G.Maunder // J Psychosom Res. 1998. — V.44. — N1. — P.91−105.
436. McCleane, G.J. A phase 1 study of the cholecystokinin (CCK) B antagonist L-365,260 in human subjects taking morphine for intractable non-cancer pain. Text. / G.J.McCleane // Neurosci Lett. -2002. V.332. — N3. — P.210−2.
437. McCracken, M.L. A transmembrane amino acid in the GABAA receptor 32 subunit critical for the actions of alcohols and anesthetics. [Text. / M.L.McCracken, C.M.Borghese, J.R.Trudell, R.A.Harris // J Pharmacol Exp Ther. 2010. — V.335. — N3. — P.600−6.
438. McDonald, I. M CCK2receptor antagonists. Text. / I. MMcDonald // Exp. Opin. Ther. Patents. 2001. — V.ll. — P.445−462.
439. McGrath, M. Association between catechol-O-methyltransferase and phobic anxiety. Text. / M. McGrath, I. Kawachi, A. Ascherio, G.A.Colditz, D.J.Hunter, I. De Vivo // The American journal of psychiatry 2004. — N161. — P.1703−1705.
440. McLaughlin, J.P. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Text. / J.P.McLaughlin, S. Li, J. Valdez, T.A.Chavkin, C. Chavkin //
441. Neuropsychopharmacol 2006. — N31. — P. 1241−1248.
442. McLaughlin, J.P. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. Text. / J.P.McLaughlin, M. Marton-Popovici, C. Chavkin // J Neurosci 2003. — N23. — P.5674−5683.
443. Mendlewicz, J. Minireview: Molecular genetics in affective illness. Text. / J. Mendlewicz, S. Sevy, K. Mendelbaum // Life Sci. -1993. -V.52.-N3.-P.231−42.
444. Menozzi, D. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. / D. Menozzi, J.D.Gardner, P.N.Maton // Am.J.Physiol. P. G73-G79. — 1989. — P.257. — URL: http://www.ncbi.nlm.nih.gov/pubmed/2 473 654.
445. Michaels, C.C. Early postnatal stress alters place conditioning to both mu-and kappa-opioid agonists. Text. / C.C.Michaels, S.D.Holtzman // J.Pharmacol.Exp.Ther. 2008. — V.325. — N1. -P.313−8.
446. Michaels, C.C. Early Postnatal Stress Alters Place Conditioning to Both and K-Opioid Agonists. Text. / C.C.Michaels // JPET -2008. -N325. -P.313−318.
447. Mikkelson, E.J. School avoidance and social phobia triggered by haloperidol in patients with Tourette’s syndrome. Text. / E.J.Mikkelson, J. Deltor, D.J.Cohen // Am J Psychiatry 1981. -N138. -P.1572−6.
448. Millan, M.J. The neurobiology and control of anxious states. Text. / M.J.Millan // Prog. Neurobiol. 2003. — V.70. — N2. — P.83−244.
449. Miller, K.K. Cholecystokinin increases GAB A release by inhibiting a resting K+ conductance in hippocampal interneurons, Text. / K.K.Miller, A. Hoffer, K.R.Svoboda, C.R.Lupica // J Neurosci. 1997. — V.17. — N13. — P.4994−5003.
450. Mitchell, J.M. Cholecystokinin is necessary for the expression of morphine conditioned place preference Text. / J.M.Mitchell, L.J.Bergren, K.S.Chen, H.L.Fields // Pharmacol Biochem Behav. -2006. V.85. — N4. — P.787−95.
451. Mohamed, S. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. Text. / S. Mohamed, R.A.Rosenheck // J Clin Psychiatry -2008. V.69. — N6. — P.959−65.
452. Moorman, D.E. Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol— preferring Sprague—Dawley rats. Text. / D.E.Moorman, G. Aston-Jones // Alcohol. 2009. — V.43. — N5. — P.379−86.
453. Moran, T.H. Two brain cholecystokinin receptors: implications for behavioral actions. Text. / T.H.Moran, P.H.Robinson, M.S.Goldrich, P.R.McHugh // Brain Res 1986. — V.362. — P. 175−9.
454. Moran, T.H. Neurobiology of cholecystokinin. Text. / T.H.Moran, G.J.Schwartz // Crit Rev Neurobiol 1994. — V.9. — P. l-28.
455. Mori, T. Sigma-1 receptor function is critical for both the discriminative stimulus and aversive effects of the kappa-opioid receptor agonist U-50488H. Text. / T. Mori, K. Yoshizawa, M. Nomura, K. Isotani // Addict Biol. 2011. — P. Epub ahead of print].
456. Morilak, D.A. Role of brain norepinephrine in the behavioral response to stress. Text. / D.A.Morilak, G. Barrera, D.J.Echevarria,
457. A.S.Garcia, A. Hernandez, S. Ma, C.O.Petre // Prog Neuropsychopharmacol Biol Psychiatry. 2005. — V.29. — N8. -P.1214−24.
458. Moroz, G. High-potency benzodiazepines: recent clinical results. Text. / G. Moroz // J Clin Psychiatry. 2004. — V.65. — Nsuppl 5. — P.13−18.
459. Mosher, J.T. Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning. Text. / J.T.Mosher, M.F.Johnson, L.S.Birkemo, G.N.Ervin // Peptides. 1996. — V. 17. — N3. — P.483−8.
460. Muigg, P. Differential stress-induced neuronal activation patterns in mouse lines selectively bred for high, normal or low anxiety. Text. / P. Muigg, S. Scheiber, P. Salchner, M. Bunck, R. Landgraf, N. Singewald // PLoSOne 2009. — V.4. — N4. — P. E5346.
461. Mundo, E. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Text. / E. Mundo, G. Maina, C. Uslenghi // Int Clin Psychopharmacol. 2000. — V.15. — N2. — P.69−76.
462. Munjack, DJ. Generalized anxiety disorder: some biochemical aspects. Text. / D.J.Munjack, P.L.Baltazar, V. DeQuattro, P. Sobin, R. Palmer, A. Zulueta, B. Crocker, R. Usigli, G. Buckwalter, M. Leonard // Psychiatry Res. 1990. — V.32. — N1. — P.35−43.
463. Munoz, M NK-1 receptor antagonists: a new paradigm inpharmacological therapy. Text. / MMunoz, R. Covenas // Curr Med Chem. -2011. V.18. -N12. — P. 1820−31.
464. Murck, H. Magnesium and affective disorders. Text. / H. Murck // Nutr. Neurosci. 2002. — V.5. — N6. — P.375−389.
465. Na, H-R. The Genetic Basis of Panic Disorder. Text. / H-R.Na, E-H.Kang, H-H.Lee, B-H.Yu // J. Korean Med Sci 2011. -V.26. — P.701−710.
466. Nealey, K.A. K-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats. Text. / K.A.Nealey, A.W.Smith, S.M.Davis, D.G.Smith, B.M.Walker
467. Neuropharmacology. 2011. — V.61. — N1−2. — P.35−42.
468. Ness, T.J. Visceral pain: a review of experimental studies. Text. / T.J.Ness, G.F.Gebhart // Pain. 1990. — V.41. — N2. — P. 167 234.
469. Newman, S.C. A population-based family study of DSM-III generalized anxiety disorder. Text. / S.C.Newman, R.C.Bland // Psychol Med. 2006. — V.36. — N9. — P. 1275−81.
470. Nicolini, H. Overview of genetics and obsessive-compulsive disorder. Text. / H. Nicolini, P. Arnold, G. Nestadt, N. Lanzagorta, J.L.Kennedy // Psychiatry Res. 2008. — N170. — P.7−15.
471. Njung’e, K. Evaluation of marble-burying behavior as a model of anxiety. Text. / K. Njung'e, S.L.Handley // PharmacolBiochem Behav 1991. — N38. — P.63−67.
472. Noble, F. Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Text. / F. Noble,
473. M.Derrien, B.P.Roques // Br. J. Pharmacol. 1993. — V.109. — P. 10 641 070.
474. Noble, F. The role of CCK2 receptors in the homeostasis of the opioid system. Text. / F. Noble, B.P.Roques // Drugs Today (Bare). -2003. V.39. -Nil.- P.897−908.
475. Noble, F. CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology. Text. / F. Noble, B.P.Roques // Progress in Neurobiology 1999a. — V.58. — P.349−379.
476. Noguchi, T. Effects of psychological stress on monoamine systems in subregions of the frontal cortex and nucleus accumbens of the rat. Text. / T. Noguchi, Y. Yoshida, S. Chiba // Brain Res. 2001. -V.916. — N1−2. — P.91−100.
477. Noyes, R. Jr Comorbidity in generalized anxiety disorder. Text. / RJrNoyes // Psychiatr Clin North Am. 2001. — V.24. — N1. — P.41−55.
478. Noyes, R.Jr. Diazepam versus alprazolam for the treatment of panic disorder. Text. / R.Jr.Noyes, D. Burrows, J.H.Reich, F.K.Judd, M.J.Garvey, T.R.Norman, B.L.Cook, P. Marriott // J Clin Psychiatry.1996. V.57. — N8. — P.349−55.
479. Noyes, R.Jr. A family study of generalized anxiety disorder. Text. / R.Jr.Noyes, C. Clarkson, R.R.Crowe, W.R.Yates,
480. C.M.McChesney // Am J Psychiatry. 1987. — V.144. — N8. — P. 101 924.
481. Nugent, N.R. Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Text. / N.R.Nugent, A.R.Tyrka, L.L.Carpenter, L.H.Price // Psychopharmacology (Berl.) -2011.-V.214. -Nl.-P.175−196.
482. Nutt, D. Anxiety Disorders Text. / Eds.: D.Nutt. Oxford: Blackwell Publishing, 2003.
483. Nutt, D.J. Addiction: brain mechanisms and their treatment implications. Text. / D.J.Nutt // Lancet. 1996. — V.347. — N8993. -P.31−6.
484. Nutt, D.J. Brain mechanisms of social anxiety disorder. Text. /
485. D.J.Nutt, C.J.Bell, A.L.Malizia // J Clin Psychiatry. 1998. — V.59. -NSuppl 17. -P.4−11.
486. O’Neill, M.F. Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey. Text. / M.F.O'Neill, C.T.Dourish, S. JTye, S.D.Iversen // Brain. Res. 1990. — V.534. -P.287−290.
487. Occhipinti, R. Astrocytes as the glucose shunt for glutamatergic neurons at high activity: an in silico study. Text. / R. Occhipinti,
488. E.Somersalo, D. Calvetti // J Neurophysiol. 2009. — V.101. — N5. -P.2528−38.
489. Occhipinti, R. Energetics of inhibition: insights with a computational model of the human GABAergic neuron-astrocytecellular complex. Text. / R. Occhipinti, E. Somersalo, D. Calvetti // J Cereb Blood Flow Metab. 2010. — V.30. — N11. — P. 1834−46.
490. Oken, R.J. Obsessive-compulsive disorder: cerebral calcium deficiency as a possible etiologic/pathogenetic factor—a case study. Text. / R.J.Oken // Med Hypotheses. 1997. — V.49. — N6. — P.513−4.
491. Okubo, T. Polymorphisms of the CCK, CCKAR and CCKBR genes: an association with alcoholism study. Text. / T. Okubo, S. Harada // J Stud Alcohol. 2001. — V.62. — N4. — P.413−21.
492. Okubo, T. Genetic polymorphism of the CCK gene in patients with alcohol withdrawal symptoms. Text. / T. Okubo, S. Harada, S. Higuchi, S. Matsushita // Alcohol Clin Exp Res. 2000. — V.24(4 Suppl). — P.2S-4S.
493. Olivier, B, 5-HT (3) receptor antagonists and anxiety- a preclinical and clinical review. Text. / B. Olivier, I. van Wijngaarden, W. Soudijn // Eur Neuropsychopharmacol. 2000. — V.10. — N2. -P.77−95.
494. Onali, P. Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. Text. / P. Onali, S. Dedoni,
495. M.C.Olianas // J Pharmacol Exp Ther. 2010. — V.332. — N1. — P.255−65.
496. Overstreet, D. Modulation of multiple alcohol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Text. / D. Overstreet, D. Knapp, G.R.Breese // Pharmacol. Biochem.Behav. -2004. -N77. -P.405−413.
497. Overstreet, D. A 5-HT1A agonist and 5-HT2C antagonist reduce social interaction deficit induced by multiple withdrawals in rats. Text. / D. Overstreet, D. Knapp, S. Moy, G.R.Breese // Psychopharmacology 2003. — N167. — P.344−352.
498. Overstreet, D.H. Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Text. / D.H.Overstreet, D.J.Knapp, G.R.Breese // Pharmacol Biochem Behav. 2004. — V.77. — N2. — P.405−13.
499. Pallanti, S. Resistant social anxiety disorder response to Escitalopram. / S. Pallanti, L. Quercioli // 2006. URL: http://www.ncbi.nlm.nih.gov/pubmed/17 166 264.
500. Palmour, R.M. The anxiogenic effects of CCK-4 in monkeys are reduced by CCK-B antagonists, benzodiazepines or adenosine A2 agonists. Text. / R.M.Palmour, J. Brawejn, F.R.Ervin // Eur. Neuropsychopharmacol. 1992. — V.2. — P. 193−195.
501. Pande, A.C. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Text. / A.C.Pande, M. Greiner, J.B.Adams, R.B.Lydiard, M.W.Pierce // Biol. Psychiatry. 1999. — V.46. — N6. -P.860−862.
502. Panhelainen, A.E. Evidence for a role of inhibition of orexinergic neurons in the anxiolytic and sedative effects of diazepam: A c-Fos study. Text. / A.E.Panhelainen, E.R.Korpi // Pharmacol Biochem Behav. 2012. — V. 101. — N1. — P. 115−24.
503. Paterniti, S. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. Text. / S. Paterniti, C. Dufouil, A. Alperovitch // J Clin Psychopharmacol. 2002. — N22. — P.285−293.
504. Pato, M.T. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Text. / M.T.Pato, T.A.Pigott, J.L.Hill, G.N.Grover, S. Bernstein, D.L.Murphy // Am J Psychiatry. 1991. — V.148. -Nl. -P.127−9.
505. Paudice, P. Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens. Text. / P. Paudice, M. Raiteri // Br J Pharmacol. 1991. — V.103. — N3. -P. 1790−4.
506. Pauls, D.L. The genetics of obsessive compulsive disorder: a review of the evidence. Text. / D.L.Pauls // Am J Med Genetics C: Sem Med Genet. 2008. — N148. — P. 133−139.
507. Pellow, S. Validation of open: closed arm entries in elevated plus-maze as a measure of anxiety in the rat. Text. / S. Pellow, P. Chopin, S.E.File, M. Briley // Neurosci Meth J. 1985. — N14. -P, 149−167.
508. Peter, S.A. CCK1 antagonists: are they ready for clinical use? Text. / S.A.Peter, M. D'Amato, C. Beglinger // Dig Dis. 2006. -V.24. — N1−2. — P.70−82.
509. Petrovic, M. Is there a rationale for prescription of benzodiazepines in the elderly? review of the literature. Text. / M. Petrovic, A. Mariman, H. Warie, M. Afschrift, D. Pevernagie // Acta Clin Belg. 2003. — V.58. — N1. — P.27−36.
510. Philipp, E. Cholecystokinin, gastrin and stress hormone responses in marathon runners. Text. / E. Philipp, T. Wilckens, E. Friess, P. Platte, K.-M.Pirke //Peptides 1992. — V.13. — P.125−128.
511. Pierce, R.C. Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. Text. /
512. R.C.Pierce, P.W.Kalivas // J Pharmacol Exp Ther 1995. — V.275. -P.1019−29.
513. Pitman, R.K. Obsessive-compulsive disorder in Western history. Text. / R.K.Pitman // In: Current Insights in Obsessive-Compulsive Disorder / Eds.: E. Hollander, J. Zohar, A. Marazziti,
514. B.Olivier Chichester: John Wiley and Sons, 1994. — P.3−11.
515. Pitman, R.K. Psychophysiological alterations in posttraumatic stress disorder. Text. / R.K.Pitman, S.P.Orr, A.Y.Shalev, L.J.Metzger, T.A.Mellman // Semin Clin Neuropsychiatry 1999. -V.4. — N4. — P.234−41.
516. Player, M.S. Anxiety disorders, hypertension, and cardiovascular risk: a review. Text. / M.S.Player, L.E.Peterson // Int J Psychiatry Med. 2011. — V.41. — N4. — P.365−77.
517. Pohl, R.B. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Text. / R.B.Pohl, R.M.Wolkow,
518. C.M.Clary // Am J Psychiatry. 1998. — V.155. — N9. — P. l 189−95.
519. Pohorecky, L.A. Stress and alcohol interaction: an update of human research. Text. / L.A.Pohorecky // Alcohol Clin Exp Res -1991. N15. — P.438—459.
520. Pohorecky, L.A. Interaction of ethanol and stress: research with experimental animals—an update. Text. / L.A.Pohorecky // Alcohol Alcohol 1990. — N25. — P.263−276.
521. Pommier, B. Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system. Text. / B. Pommier, F. Beslot, A. Simon, M. Pophillat, T. Matsui, V. Dauge, B.P.Roques, F. Noble // J Neurosci. 2002. — V.22. — N5. — P.2005−11.
522. Porsolt, R.D. Behavioral despair in mice: a primary screening test for antidepressants Text. / R.D.Porsolt, A. Bertin, M. Jalfre // Arch Int Pharmacodyn Ther. 1977. — V.229. — N2. — P.327−36.
523. Potts, N.L.S. Magnetic resonance imaging in social phobia. Text. / N.L.S.Potts, J.R.T.Davidson, K.R.R.Krishnan, P.M.Doraiswamy // Psychiatry Res 1994. — N52. — P.35−42.
524. Powell, K.R. Evaluation of the effects of PD 134 308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Text. / K.R.Powell, J.E.Barrett // Neuropeptides 1991. — V.19 (suppl.). — P.75−78.
525. Preter, M. Panic, Suffocation False Alarms, Separation Anxiety and Endogenous Opioids. Text. / M. Preter, DF. Klein // Prog Neuropsychopharmacol Biol Psychiatry. 2008. — V.32. — N3. -P.603−612.
526. Project International Psychopharmacology Algorithm, IPAP General Anxiety Disorder (GAD) Algorithm Notes. / Project International Psychopharmacology Algorithm // URL: http://www.ipap.org/gad/index.php.
527. Prosser, J.M. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, singleblind study. Text. / J.M.Prosser, S. Yard, A. Steele, L.J.Cohen, I.I.Galynker // BMC Psychiatry 2009. — V.9. — P.25.
528. Pull, C. B Pharmacotherapy of panic disorder. Text. / C. BPull,
529. C.Damsa // Neuropsychiatr Dis Treat. 2008. — V.4. — N4. — P.779−795.
530. Putman-Casdorph, H. Chronic obstructive pulmonary disease, anxiety, and depression: state of the science. Text. / H. Putman-Casdorph, S. McCrone // Heart Lung. 2009. — V.38. — N1. — P.34−47.
531. Ramboz, S. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Text. / S. Ramboz, R. Oosting,
532. D.A.Amara, H.F.Kung, P. Blier, M. Menelsohn // Proc Natl Acad Sei USA- 1998. N95. — P.14 472−81.
533. Ramos, A. A multiple-test study of anxiety-related behaviours in six inbred rat strains. Text. / A. Ramos, O. Berton, P. Mormede, F. Chaouloff// Behav Brain Res. 1997. — V.85. — N1. — P.57−69.
534. Rasmussen, K. The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle Text. / K. Rasmussen, D. Helton, J.E.Berger, E. Scearce //Neuroreport. 1993. — V.5. — N2. — P. 154−6.
535. Rataud, J. «Anxiolytic» effect of CCK-antagonists on plus-maze behavior in mice. Text. / J. Rataud, F. Darche, O. Piot, J.M.Stutzmann, G.A.Bohme, J.-C.Blanchard // Brain Res. 1991. -V.548. — P.315−317.
536. Ravindran, L.N. Pharmacotherapy of post-traumatic stress disorder Text. / L.N.Ravindran, M.B.Stein // Curr Top Behav Neurosci. 2010. — N2. — P.505−25.
537. Reddy, P.V. Intrastrain variations in anxiolytic effect of nitrazepam in mice. Text. / P.V.Reddy, K. Devi // Indian J.Physiol. Pharmacol. 2006. — V.50. — N3. — P.309−312.
538. Redmond, D.Jr. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety Text. / D.Jr.Redmond, Y.H.Huang // .Life Sci. 1979. — V.25. — N26. -P.2149−62.
539. Rehfeld, J.F. On the tissue-specific processing of procholecystokinin in the brain and gut~a short review. Text. / J.F.Rehfeld, J.R.Bungaard, L. Friis-Hansen, J.P.Goetze // J Physiol Pharmacol. 2003. — V.54. — NSuppl 4. — P.73−9.
540. Rehfeld, J.F. CCK and anxiety: Introduction. Text. /
541. J.F.Rehfeld // In: Multiple cholecystokinin receptors in the CNS / CooprDourish C.T. Oxford: Oxford University Press, 1992.
542. Rehfeld, J.F. The biology of cholecystokinin and gastrin peptides. Text. / J.F.Rehfeld, L. Friis-Hansen, J.P.Goetze, T.V.Hansen // Curr Top Med Chem. 2007. — V.7. — N12. — P. l 154−65.
543. Rehfeld, J.F. Characterization of preprocholecystokinin products in the porcine cerebral cortex. Evidence of different processing pathways. Text. / J.F.Rehfeld, H.F.Hansen // J. Biol. Chem. 1986. — V.261. — P.5832−5840.
544. Rehfeld, J.H. Molecular forms and regional distribution of cholecystokinin in the central nervous system Text. / J.H.Rehfeld, F.C.Nielsen // In: Cholecystokinin and Anxiety / Eds.: BradwejnE -Austin: RG Landes Company, 1995. P.33−56.
545. Reiss, D. Effects of social crowding on emotionality and expression of hippocampal nociceptin/orphanin FQ system transcripts in mice. Text. / D. Reiss, A. Wolter-Sutter, W.Q.Krezel, A.M.Ouagazzal // Behav. Brain Res. 2007. — V. l84. — N2. — P. 167 173.
546. Rex, A. Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety. Text. / A. Rex, T. Barth, J.P.Voigt, A.M.Domeney, HFink // Neurosci. Lett 1994. -V.l72. — P. 139−42.
547. Rex, A. Effects of cholecystokinin-receptor agonists on cortical
548. HT release in guinea pigs on the X-maze. Text. / A. Rex, H. Fink // Peptides. 1998. — V. 19. — N3. — P.519−26.
549. Riaza Bermudo-Soriano, C. New perspectives in glutamate and anxiety. Text. / C. Riaza Bermudo-Soriano, M.M.Perez-Rodriguez, C. Vaquero-Lorenzo, E. Baca-Garcia // Pharmacol Biochem Behav. -2012. V.100. — N4. — P.752−74.
550. Rihs, M. Caffeine consumption in hospitalized psychiatric patients. Text. / M. Rihs, C. Muller, P. Baumann // Eur Arch Psychiatry Clin Neurosci 1996. — N246. — P.83−92.
551. Rivie’re, P.J.M. Molecular Targets for GI Diseases Text. / P.J.M.Rivie're, J.L.Junien // In: Drug Development / Eds.: T.S.Gaginella Totowa: Humana Press., 2000. — P.203−238.
552. Roberts, A.J. Mice lacking 5-HT7 receptors show specific impairments in contextual learning. Text. / A.J.Roberts, T. Krucker, C.L.Levy, K.A.Slanina, J.G.Sutcliffe, P.B.Hedlund // Eur J Neurosci -2004. -N19. -P.1913−1922.
553. Rocca, P. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Text. / P. Rocca, A.M.Beoni, CEva, P. Ferrero, E. Zanalda, L. Ravizza // Biol Psychiatry 1998. — V.43. — N10. — P.767−73.
554. Rocca, P. Paroxetine efficacy in the treatment of generalized anxiety disorder. Text. / P. Rocca, V. Fonzo, M. Scotta, E. Zanalda, L. Ravizza // Acta Psychiatr Scand. 1997. — V.95. — N5. — P.444−50.
555. Rodrigues Torres, A. Epidemiology of obsessive-compulsive disorder: A review. Text. / A. Rodrigues Torres, M.C.Pereira Lima // Rev Bras Psiquiatr. 2005. — N27. — P.237−242.
556. Rodriguez, F.D. Targeting opioid and neurokinin-1 receptors to treat alcoholism. Text. / F.D.Rodriguez, R. Covenas // Curr Med
557. Chem. 2011. — V.18. — N28. — P.4321−34.
558. Rodriguez, M. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. Text. / M. Rodriguez, M.F.Lignon, M.C.Galas, M. Amblard, J. Martinez // Mol Pharmacol. 1990. — V.38. — N3. — P.333−41.
559. Roques, B.P. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Text. / B.P.Roques, F. Noble, V. Dauge, M.C.Fornie-, A. Beaumont // Pharmacol. Rev. -1993. V.45. -P.87−146.
560. Rotzinger, S. Cholecystokinin modulation of mesolimbic dopamine function: regulation of motivated behaviour. Text. / S. Rotzinger, DE. Bush, F.J.Vaccarino // Pharmacol Toxicol. 2002. -V.91. — N6. — P.404−13.
561. Rotzinger, S. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Text. / S. Rotzinger, D.A.Lovejoy, L.A.Tan // Peptides. 2010. — V.31. — N4. — P.736−56.
562. Roy-Byrne, P.P. The GABA-Benzodiazepine Receptor Complex: Structure, Function, and Role in Anxiety. Text. / P.P.Roy-Byrne // J Clin Psychiatry. 2005. — V.66. — N2. — P. 14−20.
563. Saito, A. Cholecystokinin receptors in the brain: characterization and distribution. Text. / A. Saito, H. Sankaran, I.D.Goldfine, J.A.Williams // Science 1980. — V.208. — P. 1155−1156.
564. Sajdyk, T.J. Interactions between NPY and CRF in the amygdala to regulate emotionality. Text. / T.J.Sajdyk, A. Shekhar, D.R.Gehlert // Neuropeptides. 2004. — V.38. — N4. — P.225−34.
565. Salvador-Carulla, L. Costs and offset effect in panic disorders.
566. Text. / L. Salvador-Carulla, J. Segui, P. Fernandez-Cano, J. Canet // Br J Psychiatry 1995. — V.27. — P.23−8.
567. Sano, H. Characterization of the bombesin-like peptide receptor family in primates. Text. / H. Sano, S.D.Feighner, D.L.Hreniuk, H. Iwaasa, A.W.Sailer, J. Pan, M.L.Reitman, A. Kanatani, A.D.Howard, C.P.Tan // Genomics. 2004. — V.84. — N1. — P. 139−46.
568. Sartori, S.B. Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions. Text. / S.B.Sartori, M. Hauschild, M. Bunck, S. Gaburro, R. Landgraf, N. Singewald // PLoS One. 20 116. — N6. — P. E 16 849.
569. Sartori, S.B. The clinical implications of mouse models of enhanced anxiety. Text. / S.B.Sartori, R. Landgraf, N. Singewald // Future Neurol. -2011a. -V.6. N4. -P.531−571.
570. Saxena, S. Paroxetine treatment of compulsive hoarding. Text. / S. Saxena, A.L.Brody, K.M.Maidment, L.R.Jr.Baxter // J Psychiatr Res. 2007. — N41. — P.481−487.
571. Sfcarpignato, C. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretionand growth in the rat. Text. / C. Scarpignato, G. Varga, I. Dobronyi, M. Papp // Br J Pharmacol. 1989. — V.96. — N3. — P.661−9.
572. Schank, J.R. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Text. / J.R. Schank, A.L.Goldstein, K.E.Rowe, C.E.King, F.I.Carroll, A. Thorsell, M. Heilig // Addict Biol. 2012. — V. 17. — N3. — P.634−47.
573. Schiller, P.W. Bi- or multifunctional opioid peptide drugs. Text. / P.W.Schiller // Life Sei. 2010. — V.86. — N15−16. — P.598−603.
574. Schmidt, H.D. Peripheral BDNF Produces Antidepressant-Like Effects in Cellular and Behavioral Models. Text. / H.D.Schmidt, R. SDuman // Neuropsychopharmacology. 2010. — V.35. — N12. -P.2378−2391.
575. Schneider, R. Effect of intranasally administered cholecystokinin on encoding of controlled and automatic memory processes. Text. / R. Schneider, J. Osterburg, A. Buchner, R. Pietrowsky // Psychopharmacology (Berl) 2009. — N202. — P.559−567.
576. Schneier, F.S. Social Anxiety Disorder and Alcohol Use
577. Disorder Comorbidity in the National Epidemiologie Survey on Alcohol and Related Conditions. Text. / F.S.Schneier, T.E.Foose,
578. D.S.Hasin, R.G.Heimberg, Sh.L.Liu, B.F.Grant, C. Blanco // Psychol Med. 2010. — V.40. — N6. — P.977−988.
579. Schroeder, M. Anxiety-like behavior and locomotion in CCK1 knockout rats as a function of strain, sex and early maternal environment. Text. / M. Schroeder, A. Weiler // Behav Brain Res. -2010. V.211. — N2. — P.198−207.
580. Schweizer, E. Lorazepam vs. alprazolam in the treatment of panic disorder. Text. / E. Schweizer, R. Pohl, R. Balon, I. Fox, K. Rickels, V.K.Yeragani // Pharmacopsychiatry. 1990. — V.23. — N2.- P.90−3.
581. Schweizer, E. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Text. /
582. E.Schweizer, K. Rickels // Acta Psychiatr Scand Suppl. 1998. — V.98.- Ns393. P.95−101.
583. Schweizer, E. The Fourth Generation of Progress Text. /
584. E.Schweizer, K. Rickels, E.H.Uhlenhuth // In: Psychopharmacology /
585. F.E.Bloom Raven Press, 1995. — V. l 14. — P.1349−1359.
586. Sen, S. Serotonin Transporter and GABAA Alpha 6 Receptor Variants Are Associated With Neuroticism. Text. / S. Sen, S. Villafuerte, R. Nesse, S.F.Stoltenberg, J. Hopcian, L. Gleiberman, A. Weder, M. Burmeister // Biol Psychiatry. 2004. — V.55. — N3. -P.244−9.
587. Sengupta, J.N. Effects of kappa opioids in the inflamed rat colon. Text. / J.N.Sengupta, A. Snider, X. Su, G.F.Gebhart // Pain. -1999. У.19. — N2−3. — P.175−85.
588. Seredenin, S.B. Pharmacogenetic analysis of mechanisms ofemotional stress: effects of benzodiazepines. Text. / S.B.Seredenin, Yu.A.Blednov, B.A.Badyshtov, M.L.Gordey, Y.A.Nagovitsina // Ann 1st Super Sanita. 1990. — V.26. — N1. — P.81−7.
589. Sevy, S. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Text. / S. Sevy, G.N.Papadimitriou, D.W.Surmont, S. Goldman, J. Mendlewicz //Biol Psychiatry. 1989. — V.25. — N12. — P.141−52.
590. Shehi, M. Treatment of panic attacks with alprazolam and propranolol. Text. / M. Shehi, W.M.Patterson // Am J Psychiatry. -1984. V.141. — N7. — P.900−1.
591. Shemyakin, M.M. Topochemical investigations of peptide systems. Text. / M.M.Shemyakin, Y.A.Ovchinnikov, V.T.Ivanov // Angew. Chem. Int. 1969. — V.8. — P.492−9.
592. Shin, J. Phospholipase C? 4 in the medial septum controls cholinergic theta oscillations and anxiety behaviors. Text. / J. Shin, G. Gireesh, S. W, Kim // J. Neurosci. 2009. — V.29. — N49. — P. 1 537 515 385.
593. Shinnick-Gallagher, P. L-type voltage-gated calcium channels are involved in the in vivo and in vitro expression of fear conditioning. Text. / P. Shinnick-Gallagher, M.G.McKernan, J. Xie, F. Zinebi // Ann N Y Acad Sei. 2003. — N985. — P. 135−49.
594. Siepmann, M. Modelling Anxiety in Humans for Drug Development. Text. / M. Siepmann, P. Joraschky // Current
595. Neuropharmacology 2007. — V.5.
596. Sillaber, I. Stress and alcohol drinking. Text. / I. Sillaber, M.S.Henniger // Ann Med 2004. — N36. — P.596−605.
597. Singh, L. The behavioral properties of CI-988, a selective cholecystokinin-B receptor antagonist. Text. / L. Singh, M.J.Field, J. Hughes // Br. J. Pharmacol. 1991a. — V. 104. — P.239−245.
598. Singh, L. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Text. / L. Singh, A.S.Lewis, M.J.Field, J. Hughes, G.N.Woodruff // Proc Natl Acad Sci U S A -19 916.-V.88.-P.1130−3.
599. Sinha, R. How does stress increase risk of drug abuse and relapse? Text. / R. Sinha // Psychopharmacology 2001. — N158. -P.343−359.
600. Skre, I. A twin study of DSM-III-R anxiety disorders. Text. / I. Skre, S. Onstad, S. Torgersen, S. Lygren, E. Kringlen // Acta Psychiatr Scand. 1993. — V.88. — N2. — P.85−92.
601. Smith, R.J. Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Text. / R.J.Smith, G. Aston-Jones // Brain Struct Funct. -2008. -V.213. N1−2. -P.43−61.
602. Spengler, D. Differential signal transduction by five splice variants of the PACAP receptor. Text. / D. Spengler, C. Waeber, C. Pantaloni, F. Holsboer, J. Bockaert, P.H.Seeburg, L. Journot // Nature (Lond.) 1993. — V.365. — P.170−174.
603. Spiegel, D.A. Benzodiazepines and exposure-based cognitive behavior therapies for panic disorder: conclusions from combined treatment trials. Text. / D.A.Spiegel, T.J.Bruce // Am J Psychiatry. -1997. V.154. — N6. — P.773−81.
604. Sramek, J.J. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Text. / J.J. Sramek, M.S.Kramer, S.A.Reines, N.R.Cutler // Anxiety. 1994−1995. — V.l. -N3. — P.141−3.
605. Stanford, S.C. Anxiety Text. / S.C.Stanford // In: Neurotransmitters, Drugs and Brain Function. / R. Webste John Wiley & Sons Ltd, 2001. — P.395−435.
606. Stein, D.J. A neuro-evolutionary approach to the anxiety disorders. Text. / D.J.Stein, J.C.Bouwer // Anxiety Disord. 1997. -V.ll. -N4. -P.409−429.
607. Stein, D.J. Pharmacotherapy for post traumatic stress disorder (PTSD). Text. / D.J.Stein, J.C.Ipser, S. Seedat // Cochrane Database Syst Rev 2006. — N1. — P. CD002795.
608. Stein, M.B. Public health perspectives on generalized anxiety disorder. Text. / M.B.Stein // J Clin Psychiatry. 2004. — V.65. -NSuppl 13. — P.3−7.
609. Stein, M.B. Lymphocyte P-adrenoceptors in social phobia. Text. / M.B.Stein, L.L.Huzel, S.M.Delaney // Biol Psychiatry 1993. -N34. -P.45−50.
610. Suridjan, I. Dopamine response to psychosocial stress in humans and its relationship to individual differences in personalitytraits. / I. Suridjan, I. Boileau, M. Bagby, P.M.Rusjan, R. Mizrahi //. -2012. URL: http://www.ncbi.nlm.nih.gov/pubmed/22 475 321.
611. Suzuki, M. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Text. / M. Suzuki, C.T.Beuckmann, K. Shikata, H. Ogura, T. Sawai // Brain Res. 2005. -V.1044. -Nl. -P.l 16−21.
612. Swartz, C.M. Betaxolol in anxiety disorders. Text. / C.M.Swartz // Ann Clin Psychiatry. 1998. — V. 10. — N1. — P.9−14.
613. Szelenyi, Z. Cholecystokinin and thermoregulation — a minireview. Text. / Z. Szelenyi // Peptides 2001. — V.22. — P. 124 550.
614. Sztainberg, Y. An anxiolytic role for CRF receptor type 1 in the globus pallidus. Text. / Y. Sztainberg, Y, Kuperman, N. Justice, A. Chen // J Neurosci. 2011. — V.31. — N48. — P. 17 416−24.
615. Sztainberg, Y. The anxiolytic effect of environmental enrichment is mediated via amygdalar CRF receptor type 1. Text. / Y. Sztainberg, Y. Kuperman, M. Tsoory, M. Lebow, A. Chen // Mol. Psychiatry. 2010. — V. 15. — N9. — P.905−917.
616. Talkad, V.D. Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Text. / V.D.Talkad, K.P.Fortune, D.A.Pollo, G.N.Shah, S.A.Wank, J.D.Gardner // Proc. Natl. Acad. Sei. U.S.A. 1994. — V.91. — P.1868−1872.
617. Tallent, M. The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells. Text. / M. Tallent, M.A.Dichter, G.I.Bell, T. Reisine // Neuroscience 1994. -V.63. — P.1033−1040.
618. Taniguchi, H. Pharmacological profile of T-0632, a novel potent and selective CCK-A receptor antagonist, in vivo. Text. / H. Taniguchi, N. Yazaki, E. Yomota, T. Shikano, T. Endo, M. Nagasaki // Eur. J. Pharmacol. 1996. — V.312. — P.227−233.
619. Tasan, R.O. Altered GABA transmission in a mouse model of increased trait anxiety. Text. / R.O.Tasan, A, Bukovac, Y.N.Peterschmitt, S.B.Sartori, R. Landgraf, N. Singewald, G. Sperk // Neuroscience. 2011. — V. 183. — P.71 -80.
620. Tassone, D.M. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders Text. / D.M.Tassone, E. Boyce, J. Guyer, D. Nuzum // Clin Ther. 2007. — V.29. — N1. — P.26−48.
621. Tate, S. Characteristics of life stressors predictive of substance treatment outcomes. Text. / S. Tate, J. McQuaid, S. Brown // J Subst Abuse Treat 2005. — N29. — P. 107−115.
622. Tedeshi, R.E. Effects of various centrally acting drugs on fighting behavior of mice. Text. / R.E.Tedeshi, D.H.Tedeshi, A. Mucha, L. Cook, P.A.Mattis, E.J.Fellows, M.A.Bozarth, C.C.Michaels // J. pharmacol. Exp. Ther. 1959. — N125. — P.28 — 34.
623. Thompson, A.J. The 5-HT3 receptor as a therapeutic target. Text. / A.J.Thompson, S.C.R.Lummis // Expert Opin Ther Targets. -2007. V. 11. — N4. — P.527−540.
624. Tiihonen, J. Dopamine reuptake site densities in patients with social phobia. Text. / J. Tiihonen, J. Kuikka, K. Bergstrom, U. Lepola,
625. H.Koponen, E. Leinonen // Am J Psychiatry. 1997. — N154. — P.239−242.
626. Tiller, J.W. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Text. / J.W.Tiller, C. Bouwer, K. Behnke // Eur Arch Psychiatry Clin Neurosci 1999. -V.249 Suppl 1. -P.S7−10.
627. Tillfors, M. Why do some individuals develop social phobia? A review with emphasis on the neurobiological influences. Text. / M. Tillfors // Nord J Psychiatry. 2004. — V.58. — N4. — P.267−76.
628. Todtenkopf, M.S. Effects of K-opioid receptor ligands on intracranial self-stimulation in rats. Text. / M.S.Todtenkopf, J.F.Marcus, P. S.Portoghese, W.A.Jr.Carlezon // Psychopharmacol -2004. -N172. -P.463−470.
629. Toth, I. Social Fear Conditioning: A Novel and Specific Animal Model to Study Social Anxiety Disorder. Text. / I. Toth,
630. D.Neumann, D.A.Slattery // Neuropsychopharmacology. 2012.
631. Tsai, S.J. Association study of adenosine A2a receptor (1976C>T) genetic polymorphism and mood disorders and age ofonset. Text. / S.J.Tsai, C.J.Hong, S.J.Hou, F.C.Yen // Psychiatr Genet 2006. — N16. — P.185.
632. Tsunoda, I. Massive Apoptosis in Lymphoid Organs in Animal Models for Primary and Secondary Progressive Multiple Sclerosis. Text. / I. Tsunoda, J.E.Libbey, L.-Q.Kuang, E.J.Terry, R.S.Fujinami // Am J Pathol. 2005. — V.167. — N6. — P. 1631−1646.
633. Tsunoda, Y. High-affinity CCK receptors are coupled to phospholipase A2 pathways to mediate pancreatic amylase secretion. / Y. Tsunoda, C. Owyang // Am. J. Physiol. 1995. — P.269. — URL: http://www.ncbi.nlm.nih.gov/pubmed/7 573 455.
634. Tsunoda, Y. Structural requirements of CCK analogues to differentiate second messengers and pancreatic secretion. / Y. Tsunoda, H. Yoshida, C. Owyang // Am. J. Physiol. 1996. — P.271. — URL: http://www.ncbi.nlm.nih.gov/pubmed/87 601 012.
635. Turner, SM Social phobia: a comparison of behavior therapy and atenolol. Text. / SMTurner, D. Biedel, R.G.Jacob // J Consult Clin Psychol 1994. — N62. — P.350−8.
636. Uhart, M. GABRA6 Gene Polymorphism and an Attenuated Stress Response. Text. / M. Uhart, M.E.McCaul, L.M.Oswald, L. Choi, G.S.Wand // Mol Psychiatry. 2004. — V.9. — Nil. — P.998−1006.
637. Uhart, M. Stress, alcohol, and drug interaction: an update of human research. Text. / M. Uhart, G.S.Wand // Addiction Biol -2008. -N14. -P.43−64.
638. Vaccarino, F.J. Nucleus accumbens dopamine-CCK interactionsin psychostimulant reward and related behaviors. Text. / F.J.Vaccarino // Neurosci. Biobehav Rev 1994. — V.18. — P.207−14.
639. Vaccarino, F.J. Antagonism of cholecystokinin function in the rostral and caudal nucleus accumbens: differential effects on brain stimulation reward. Text. / F.J.Vaccarino, A.L.Vaccarino // Neurosci Lett 1989. -V.97. -P. 151−6.
640. Valdez, G.R. Kappa opioid regulation of anxiety-like behavior during acute ethanol withdrawal. Text. / G.R.Valdez, E. Harshberger // Pharmacol Biochem Behav. 2012. — V. 102. — N1. — P.44−7.
641. Valenca, A.M. Clonidine in respiratory panic disorder subtype. Text. / A.M.Valenca, A.E.Nardi, M.A.Mezzasalma, I. Nascimento, F. Lopes, W.A.Zin, M. Versiani // Arq Neuropsiquiatr. 2004. — V.62. -P.396−8.
642. Valverde, O. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. Text. / O. Valverde, R. Maldonado, M.C.Fournie-Zaluski, B.P.Roques // J Pharmacol Exp Ther. 1994. — V.270. — N1. — P.77−88.
643. Valverde, O. Cholecystokinin modulates the aversive component of morphine withdrawal syndrome in rats. Text. / O. Valverde, B.P.Roques // Neurosci Lett. 1998. — V.244. — N1. -P.37−40.
644. Vanderhaeghen, J.J. New peptide acting in the vertebrate CNS with anti-gastrin antibodies. Text. / J.J.Vanderhaeghen, J.C.Signeau, W. Gepts // Nature 1975. — V.257. — P.604−605.
645. Vanhoutte, P.M. XI. International union of pharmacology. Recommendations for nomenclature of new receptor subtypes. Text. / P.M.Vanhoutte, P.P.A.Humprey, M. Spedding // Pharmacol. Rev. -1996. V.48.-P.l-2.
646. Vasar, E. Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse. Text. / E. Vasar, J. Harro, A. Lang, A. Pold, A. Soosaar // Psychopharmacology (Berlin) 1991. — V.105. — P.393−399.
647. Vasar, E. CCK receptors and anxiety in rats. In: Text. / E. Vasar, J. Harro, A. Pold, A. Lang // In: Multiple cholecystokinin receptors in the CNS. / CooperDourish CT Oxford: Oxford University Press, 1992. — P. 143−8.
648. Vasar, E. Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Text. / E. Vasar, A. Lang, J. Harro, M. Bourin, J. Bradwejn // Neuropharmacology 1994. — V.33. — P.729−35.
649. Vengeliene, V. Neuropharmacology of alcohol addiction. Text. / V. Vengeliene, A. Bilbao, A. Molander, R. Spanagel // Br JPharmacol 2008. — N154. — P.299−315.
650. Veraksits, A. Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Text. / A. Veraksits, K. Runkorg, K. Kurrikoff, S. Raud, U. Abramov, T. Matsui,
651. M.Bourin, S. Koks, E. Vasar // Psychopharmacology (Berl) 2003. -V.166. -N2. -P. 168−75.
652. Vickroy, T.W. Pharmacological and mechanistic studies of cholecystokinin-facilitated 3H. dopamine efflux from rat nucleus accumbens. [Text] / T.W.Vickroy, B.R.Bianchi // Neuropeptides -1989. V.13.-P.43−50.
653. Vogel, H.G. Drug discovery and evaluation. Pharmacological • assays. Text. / H.G.Vogel, W.H.Vogel. Berlin, Heidelberg: Springer-Verlag, 1997. — P.360¹²⁰.
654. Vogel, J.R. A simple and reliable conflict procedure for testing anti-anxiety agents. Text. / J.R.Vogel, B. Beer, D.E.Clody // Psychopharmacologia. 1971. — V.21. — P. 1−7.
655. Voigt, J.P. CCK-8S facilitates 5-HT release in the rat hypothalamus. Text. / J.P.Voigt, R. Sohr, H. Fink // Pharmacol Biochem Behav. 1998. — V.59. — N1. — P. 179−82.
656. Voigt, M.M. In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Text. / M.M.Voigt, R.Y.Wang // Brain Res 1984. — V.296. — P. 189−93.
657. Voigt, M.M. The effects of cholecystokinin on the in vivo release of newly synthesized 3H. dopamine from the nucleus accumbens of the rat. [Text] / M.M.Voigt, R.Y.Wang, T.C. Westfall // J Neurosci 1985. — V.5. — P.2744−9.
658. Walker, B.M. Pharmacological Evidence for a Motivational Role of K-Opioid Systems in Ethanol Dependence. Text. / B.M.Walker, G.F.Koob // Neuropsychopharmacology. 2008. — V.33. — N3. — P.643−652.
659. Wall, P.M. U-69,593 microinjection in the infralimbic cortexreduces anxiety and enhances spontaneous alternation memory in mice. Text. / P.M.Wall, C. Messier // Brain Res. 2000. — V.856. -N1−2. -P.259−80.
660. Wand, G.S. Alterations in the hypothalamic-pituitary-adrenal axis in actively drinking alcoholics. Text. / G.S.Wand, A.S.Dobs // J Clin Endocrinol Metab 1991. — N72. — P.1290−1295.
661. Wang, H. Blockade of CRF1 and CCK2 receptors attenuated the elevated anxiety-like behavior induced by immobilization stress. / H. Wang, J. Spiess, P.T.Wong, Y.Z.Zhu // 2011. URL: http://www.ncbi.nlm.nih.gov/pubmed/21 295 058.
662. Wang, H. Cholecystokinin-2 (CCK2) receptor-mediated anxiety-like behaviors in rats. Text. / H. Wang, P.T.Wong, JSpiess, Y.Z.Zhu // Neurosci Biobehav Rev 2005. — N29. — P. 1361−1373.
663. Wang, J. Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson’s disease. Text. / J. Wang, Y.M.Si, Z.L.Liu, L. Yu // Pharmacogenetics 2003. — V.13. — P.365−369.
664. Wank, S.A. Cholecystokinin receptors. Text. / S.A.Wank // Am. J. Physiol. 1995. — V.269. — P. G628-G646.
665. Wank, S.A. G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. Text. / S.A.Wank // Am. J. Physiol. 1998. — V.274. — P. G607-G613.
666. Wank, S.A. Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Text. / S.A.Wank, J.R.Pisegna, A. de Weerth // Proc. Natl. Acad. Sci. USA 1992. -V.89. — P.8691−8695.
667. Watson, J.B. Conditioned emotional reactions. Text. /
668. J.B.Watson, R. Rayner//J. Exp. Psychol. 1920. — V.3. — N1. — P. 1−14.
669. Weisberg, R.B. Overview of generalized anxiety disorder: epidemiology, presentation and course. Text. / R.B.Weisberg // J Clin Psychiatry 2009. — V.70 (Suppl. 2). — P.4−9.
670. Weizman, A. Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Text. / A. Weizman, R. Weizman // Pharmacogenomics. 2000. — V.l. — N3. — P.335−41.
671. Wendland, J.R. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Text. / J.R.Wendland, P.R.Moya, K.R.Timpano // Arch Gen Psychiatry. 2009. — N66. — P.408−416.
672. Wesolowska, A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Text. / A. Wesolowska // Pharmacol Rep 2010. — N62. — P.564−577.
673. Wesolowska, A. Effect of the selective 5-HT (7) receptor antagonist SB 269 970 in animal models of anxiety and depression.
674. Text. / A. Wesolowska, A. Nikiforuk, K. Stachowicz, E. Tatarczynska //Neuropharmacology 2006. — N51. — P.578−586.
675. White, F.J. A behavioral/systems approach to the neuroscience of drug addiction. Text. / F.J.White // J. Neurosci. 2002. — V.22. -N9. — P.3303−5.
676. White, F.J. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Text. / F.J.White, RY. Wang // Brain Res 1984. — V.300. — P. 161−6.
677. Whittle, N. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Text. / N. Whittle, LLi, W.Q.Chen // Amino Acids. 2011.
678. Widerlov, E. Influence of cholecystokinin on central monoaminergic pathways. Text. / E. Widerlov, P.W.Kalivas, M.H.Lewis // Regul Pept. 1983. — V.6. — N2. — P.99−109.
679. Wilkins, J.N. Clinical neuroendocrinology and neuropharmacology of alcohol withdrawal. Text. / J.N.Wilkins, DA. Gorelick // Recent Dev Alcohol. 1986. — N4. — P.241−63.
680. Wilson, J. CCK (B) antagonists protect against some aspects of the ethanol withdrawal syndrome. Text. / J. Wilson, H.J.Little // Pharmacol Biochem Behav. 1998a. — V.59. — N4. — P.967−73.
681. Wilson, J. Cholecystokinin system genes: Associations with panic and other psychiatric disorders. Text. / J. Wilson, D. Markie, A. Fitches // J Affect Disord. 2012. — V. 136. — N3. — P.902−8.
682. Wilson, J. CCK (B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze. Text. / J. Wilson, W.P.Watson, H.J.Little // Psychopharmacology 1998b. — V.137. — P. 120−31.
683. Wise, R.A. Brain dopamine and reward. Text. / R.A.Wise, P.P.Rompre // Annual. Rev. Psychol. 1989. — V.40. — P. 191−225.
684. Wittchen, H-U, Early Developmental Stages of Psychopharmacology Study (EDSP). Objectives and disign. Text. / H-U.Wittchen, A. Perkonigg, G. Lachner, C.B.Nelson // European Addiction Research 1998. — V.4. — P. 18−27.
685. Wolfe, M.M. Investing in the Future of GERD Text. / M.M.Wolfe, R.C.Lowe // J. Clin. Gastroenterol. 2007. — V.41. -P.209.
686. Wolkowitz, O.M. Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Text. / O.M.Wolkowitz, B. Gertz, H. Weingartner, L. Beccaria, K. Thompson, R.A.Liddle // Biol Psychiatry 1990. — V.28. — P. 169−173.
687. Woodriff, G.N. Functional role of brain CCK receptors. Text. / G.N.Woodriff, D.R.Hill, P. Boden, R. Pinnock, L. Singh, J. Hughes // Neuropeptides 1991. — V. 19, — P.45−56.
688. Xuan, Pham. Association Study between GABA Receptor Genes and Anxiety Spectrum Disorders. Text. / Pham. Xuan, SunCuie, ChenXiangning, E.J.C.G.van den Oord, M.C.Neale, K.S.Kendler, J.M.Hettema // Depress Anxiety. 2009. — V.26. -N11.-P.998−1003.
689. Yamada, K. Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. Text. / K. Yamada, E. Hattori, M. Shimizu, A. Sugaya, H. Shibuya, T. Yoshikawa // J Neural Transm 2001. — V.108. — P.837−48.
690. Yamada, K. Differential effects of social isolation upon body weight, food consumption, and responsiveness to novel and social environment in bombesin receptor subtype-3 (BRS-3) deficient mice.
691. Text. / K. Yamada, H. Ohki-Hamazaki, K. Wada // Physiol Behav. -2000. V.68. — N4. — P.555−61.
692. Yamada, K. Role of Bombesin (BN)-Like Peptides/Receptors in emotional Behavior by Comparison of Three Strains of BN-Like Peptide Receptor Knockout Mice. Text. / K. Yamada, Y. Santo-Yamada, E. Wada, K. Wada // Mol Psychiatry 2002. — V.7. — P. 113−7.
693. Yamamoto, Y. Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Text. / Y. Yamamoto, J. Akiyoshi, A. Kiyota, S. Katsuragi, T. Tsutsumi, K. Isogawa, H. Nagayama // Brain Res Bull. 2000. — V.53. — N6. — P.789−92.
694. Yang, Y.M. Cholecystokinin-8S-induced intracellular calcium signaling in acutely isolated periaqueductal gray neurons of the rat. Text. / Y.M.Yang, J.M.Chung, H. Rhim // Biol Pharm Bull. 2007. -V.30. — N2. — P.297−302.
695. Yoshida, H. Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. / H. Yoshida, Y. Tsunoda, C. Owyang //. P. G735-G747. — 1997. — P.273. — URL: http://www.ncbi.nlm.nih.gov/pubmed/9 316 479.
696. You, J.S. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Text. / J.S.You, S.Y.Hu, B. Chen, H.G.Zhang // Psychiatric genetics 2005. — N15. — P.7−11.
697. Young, E.A. Stress Hormones and Anxiety Disorders. Text. / E.A.Young, J.L.Abelson, D. Liberzon // In: Handbook of Anxiety and Fear / Eds.: RJ. Blanchard, DC. Blanchard, G. Griebel, D. Nutt Oxford: Academic Press, 2008. — P.455−473.
698. Young, E.A. Effects of estrogen antagonists and agonists on the ACTH response to restraint stress in female rats. Text. / E.A.Young, M. Altemus, V. Parkison, S. Shastry // Neuropsychopharmacology. -2001. N25. — P.:881−891.
699. Yun, H.M. The serotonin-6 receptor as a novel therapeutic target. Text. / H.M.Yun, H. Rhim // Exp Neurobiol. 2011. — V.20. -N4. — P. 159−68.
700. Zhao, Y. Remission and resurgence of anxiety-like behavior across protracted withdrawal stages in ethanol-dependent rats. Text. / Y. Zhao, F. Weiss, E.P.Zorrilla // Alcohol Clin Exp Res. 2007. -V.31. — N9. — P.1505−15.
701. Zhao, Z.L. Acupuncture Attenuates Anxiety-Like Behavior by Normalizing Amygdaloid Catecholamines during Ethanol Withdrawal in Rats Text. / Z.L.Zhao, G.W.Zhao, H.Z.Li, X.D.Yang, Y.Y.Wu, F. Lin // Evid Based Complement Alternat Med. 2011. — P.429 843.
702. Zitzmann, M. Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs. Text. / M. Zitzmann, E. Nieschlag // Eur J Endocrinol. -2001. V.144. — P.183−187.
703. Zohar, J. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Text. /
704. J.Zohar, T.R.Insel // Biol Psychiatry. 1987. — V.22. — N6. — P.667−87.
705. Zohar, J. Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment. Text. / J. Zohar, T.R.Insel, R.C.Zohar-Kadouch // ArchGen Psychiatry. 1988. — N45. — P.167−172.
706. Zwanzger, P. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. Text. / P. Zwanzger, R. Rupprecht // J Psychiatry Neurosci 2005. -V, 30.-N3.-P.167−175.